SEARCH:      Monitor Keywords |  Custom RSS

Drug, bio-affecting and body treating compositions January USPTO class patent listing 01/07

20070020176 - Contrast agent: The present invention relates to a contrast agent of Formula I V-L-Z Formula I where V is a non-peptidic vector having affinity for the Angiotensin II receptor, L is a bond, a spacer or a linker moiety and Z represents a moiety detectable in an in vivo imaging procedure of... Agent: Ge Healthcare, Inc.

20070020178 - Phospholipid ether analogs as cancer treatment agents and methods thereof: The present invention provides methods for treating, detecting and locating recurrence of cancer, radiation and chemo insensitive cancer or metastasis of cancer selected from the group consisting of Lung cancer, Adrenal cancer, Melanoma, Colon cancer, Colorectal cancer, Ovarian cancer, Prostate cancer, Liver cancer, Subcutaneous cancer, Squamous cell cancer, Intestinal cancer,... Agent: Godfrey & Kahn S.c.

20070020177 - Radiometal complex compositions: The present invention relates to stabilised technetium and rhenium metal complex compositions comprising a radioprotectant and a radiometal complex of a tropane-tetradentate chelating agent conjugate, wherein the radiometal complex is neutral. Radiopharmaceuticals comprising the stabilised metal complex compositions, and kits for the preparation of the radiopharmaceuticals are also described.... Agent: Ge Healthcare, Inc.

20070020179 - Acute leukemia and lymphoblastic lymphoma-specific cd43 epitope and use thereof: The present invention relates to a CD43 epitope expressed on human acute leukemia and lymphoblastic lymphoma cells and its use. More particularly, the present invention relates to a CD43 epitope expressed on human acute leukemia, lymphoblastic lymphoma cells, but not on mature hematopoietic cells, hematopoietic stem cells and non-hematopoietic cells,... Agent: Cantor Colburn, LLP

20070020180 - Method for determining the impact of a multicomponent natural product mixture on the biological profile of a disease within a group of living systems and the developement and quality control of natural product based medicine: The present invention provides a method for determining the impact of a multicomponent natural product mixture on the biological profile of a disease comprising the steps of: (a) determining a biological profile of the disease by comparing the biological profile of a group of living systems with symptoms of the... Agent: Nixon & Vanderhye, PC

20070020181 - Non-invasive measurement of analytes: This invention provides devices, compositions and methods for determining the concentration of one or more metabolites or analytes in a biological sample, including cells, tissues, organs, organisms, and biological fluids. In particular, this invention provides materials, apparatuses, and methods for several non-invasive techniques for the determination of in vivo blood... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070020184 - Diagnostic imaging contrast agents with extended blood retention: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical... Agent: Fish & Richardson P.C.

20070020185 - Diagnostic imaging contrast agents with extended blood retention: The present invention relates to contrast agents for diagnostic imaging with prolonged blood retention. In particular, this invention relates to novel compounds that are characterized by an image enhancing moiety (IEM); a protein plasma binding moiety (PPBM); and a blood half-life extending moiety (BHEM). This invention also relates to pharmaceutical... Agent: Fish & Richardson P.C.

20070020183 - Perfluoroalkyl-containing complexes, process for their production as well as their use: The invention relates to the subjects that are characterized in the claims, namely perfluoroalkyl-containing metal complexes with an N-alkyl group of general formula 1, process for their production and their use in NMR and x-ray diagnosis, radiodiagnosis, and radiotherapy, as well as in MRT lymphography.... Agent: Millen, White, Zelano & Branigan, P.C.

20070020182 - Quaternary nitrogen heterocyclic compounds for detecting aqueous monosaccharides in physiological fluids: Quaternary nitrogen heterocyclic boronic acid-containing compounds are described, which are sensitive to glucose and fructose, as well as a variety of other physiologically important analytes, such as aqueous chloride and iodide, and a method of using the compounds. Also disclosed is a contact lens doped with the quaternary nitrogen heterocyclic... Agent: Moore & Van Allen PLLC

20070020188 - Pharmaceutical formulation containing irritant: Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after tampering.... Agent: Davidson, Davidson & Kappel, LLC

20070020186 - Solid dosage formulations of narcotic drugs having improved buccal adsorption: The present invention provides solid dosage formulations of narcotic drugs with improved buccal adsorption. These improved characteristics are provided by the combination of the narcotic drug with an additional non-toxic soluble organic compound. The soluble organic compound contains a primary, secondary or tertiary amine group. The addition of this organic... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070020187 - Solid dosage formulations of narcotic drugs having improved buccal adsorption: Disclosed is a pharmaceutical composition in the form of a tablet suitable for dissolution in the buccal cavity, said composition comprising i) an effective amount of a narcotic active ingredient, and ii) a pharmaceutically acceptable amine having a pK of about 8 or greater, wherein the molar ratio of amine:active... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070020189 - Method of delivering compositions to substrates: Method of delivering compositions to organic substrates, particularly lumber. Method involves heating a target zone of the substrate and then applying the composition to the surface of the substrate wherein the temperature of the composition is lower than that of the target zone of the substrate. Compositions include biocidal, strength... Agent: Fish & Richardson PC

20070020193 - Dronabinol compositions and methods for using same: In various embodiments, the present invention provides pharmaceutical compositions comprising delta-9-THC and to methods of administering such compositions to a patient in need of delta-9-THC therapy.... Agent: Mayer, Brown, Rowe & Maw LLP

20070020196 - Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension: An inhalable unit dose liquid formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution or concentrated composition. The formulation is employed... Agent: Innovar, LLC

20070020190 - Medicament comprising a highly potent long-lasting beta2-agonist in combination with other active ingredients: The present invention relates to the use of a bronchodilator in combination with one or more further active ingredients for the treatment of respiratory disorders and especially asthma and chronic obstructive pulmonary disease (COPD), and to pharmaceutical compositions containing said active ingredients. In particular, the invention relates to the use... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070020194 - Nasally administered appetite suppressant: Methods are described for suppressing appetite through the intranasal administration of a sodium channel blocker. It has long been known that smell and taste are an important part of how the body prepares for a meal, for example the cephalic phase of insulin release before a meal. Depressing the sense... Agent: Knobbe Martens Olson & Bear LLP

20070020195 - Nasally administered appetite suppressants: Methods are described for suppressing appetite through the intranasal administration of a sodium channel blocker. It has long been known that smell and taste are an important part of how the body prepares for a meal, for example the cephalic phase of insulin release before a meal. Depressing the sense... Agent: Knobbe Martens Olson & Bear LLP

20070020191 - Potentiation of glucose elimination: Methods related to the treatment of diabetes and improving the efficiency of insulin utilization are provided. The method enables effective control of prandial glucose levels while reducing the risk of postprandial hypoglycemia. In particular, methods of potentiating the activity of endogenous insulin in type 2 diabetics and exogenous long-acting insulin... Agent: Preston Gates & Ellis LLP

20070020192 - Receptor specific transepithelial transport of therapeutics: The present invention relates in general to methods and products for initiating an immune response against an antigen, and in particular relates to transepithelial delivery of antigens to provoke tolerance and immunity. The present invention further relates to methods and products for the transepithelial delivery of therapeutics. In particular, the... Agent: Wolf Greenfield & Sacks, PC

20070020199 - Dispersible macromolecule compositions and methods for their preparation and use: A process for preparing ultrafine powders of biological macromolecules comprises atomizing liquid solutions of the macromolecules, drying the droplets formed in the atomization step, and collecting the particles which result from drying. By properly controlling each of the atomization, drying, and collection steps, ultrafine dry powder compositions having characteristics particularly... Agent: Nektar Therapeutics

20070020198 - Medical product containing tiotropium: The invention discloses a medical product that may be used in a treatment of respiratory disorders.... Agent: Sughrue Mion, PLLC

20070020197 - Preparation of pharmaceutical compositions containing nanoparticles: Materials and methods for preparing pharmaceutical nanoparticle suspensions or dispersions, granulations and dosage forms are disclosed. The methods employ a modular high-pressure spray homogenizer coupled to a wet granulator to form stabilized nanoparticle suspensions and granulations.... Agent: Warner-lambert Company

20070020200 - Therapeutic compositions and methods of use thereof: A method and composition for the restoration and maintenance of gingival and periodontal health are provided. The composition includes a potassium as an essential ingredient, which acts as an anti-bacterial agent. In some embodiments, the compositions include an osmotic agent other than potassium.... Agent: Salter & Michaelson The Heritage Building

20070020201 - Oral composition containing non-aggregated zinc nanoparticles: An oral composition comprising a vehicle and a zinc ion source in the form of nanoparticles that are substantially non-aggregated and methods for use of such compositions are described. The composition provides antiplaque and anti malodor benefits to the user and the inclusion of nanoparticles permits a reduction in the... Agent: Colgate-palmolive Company

20070020204 - Photoprotecting/cosmetic compositions comprising benzotriazole and bis-resorcinyltriazine: Topically applicable sunscreen/cosmetic compositions suited for the improved photoprotection of human skin and/or hair against the damaging effects of UV-irradiation, particularly solar radiation, comprise an effective SPF-maintaining and water remanence-enhancing amount of intimate admixture of (a) at least one benzotriazole first sunscreen compound and (b) at least one bis-resorcinyltriazine second... Agent: Buchanan, Ingersoll & Rooney PC

20070020203 - Skin care composition: Skin care compositions comprising certain ratios of phyllanthus Emblica extracts, licorice extracts and niacinamide. Certain embodiments provide a synergistic response to lightening/even-toning the skin. These skin care compositions comprise skin lightening/even-toning formulations, sunscreen compositions, compositions for photoprotecting skin or reducing a stretch mark or compositions for repairing damaged skin.... Agent: Millen, White, Zelano & Branigan, P.C.

20070020202 - Sunless tanning substrate: The present invention provides a sunless tanning substrate having one or more sunless tanning enhancers, which adjust the rate of color development and/or adjust or customize the color developed on the skin. The present invention further provides a method of sunless tanning comprising the step of using the sunless tanning... Agent: Charles N.j. Ruggiero Ohlandt, Greeley, Ruggiero & Perle, L.L.P.

20070020205 - Two-coat cosmetic product, uses thereof and makeup kit containing this product: Product containing a first composition and a second composition, the first composition containing at least one resin chosen from rosin and derivatives thereof, and hydrocarbon-based resins, and mixtures thereof, the resin having a number-average molecular mass of less than or equal to 10 000 g/mol, and the second composition, which... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070020207 - Cosmetic composition: A cosmetic composition effective in skin lightening or skin rejuvenation is provided. The cosmetic composition is characterized by containing sodium ions, potassium ions, calcium ions, magnesium ions, chlorine ions and HCO3 ions in a molar concentration proportion equal to that in the extracellular fluid of mammals and further containing glucose... Agent: Bacon & Thomas, PLLC

20070020206 - Use of biotin or a biotin derivative for lightening skin and treating age spots: The present invention relates to the use of biotin alone, preferably, however, with vitamin C or a derivative thereof, for the preparation of a cosmetic composition or of a pharmaceutical composition for skin-lightening purposes, for the elimination of skin color irregularities and for the treatment of senile lentigines.... Agent: Stephen M Haracz Bryan Cave

20070020209 - Makeup compositions and methods: Emulsion makeup compositions for keratinous surfaces which change color upon application, emulsion makeup compositions that match a variety of skin or hair shades in more than one skin tone category, and methods for treating keratinous surfaces with an emulsion cosmetic composition that changes color upon application.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070020208 - Modified colorants and uses of the same: Modified colorants are made from a modifying agent, such as platelet alumina, and a colorant. The colorant may be fixed to the surface of the modifying agent, optionally with a surface treatment. The colorant may not completely coat the surface of the modifying agent, and the edge of the modifying... Agent: Michael Best & Friedrich, LLP

20070020210 - Methods of reducing the perception of body odors with olfactory adaptation and cross-adapting agents: Deodorant compositions are disclosed comprising a cross-adapting agent, alone or in combination with other such agents, in an amount effective to reduce perception of malodor. Deodorant compositions are also disclosed comprising a cross-adapting agent, alone or in combination with other such agents, in an amount effective to reduce perception of... Agent: Woodcock Washburn LLP

20070020211 - Betaine with calcium and/or strontium antiperspirants: Aluminum and aluminum-zirconium antiperspirant compositions comprising basic aluminum chlorides that have a particular molecular size distribution defined by having an SEC-HPLC Band III/II ratio of at least 0.5, having SEC-HPLC Band III plus Band II area of at least 70% of the total area and having SEC-HPLC Band I content... Agent: Arthur J. Plantamura General Chemical Performance Products LLC.

20070020213 - Foamable composition combining a polar solvent and a hydrophobic carrier: The present invention relates to a foamable vehicle or cosmetic or pharmaceutical composition, comprising: (1) an organic carrier, at a concentration of 10% to 70% by weight, wherein said organic carrier concurrently comprises: (i) at least one hydrophobic organic carrier, and (ii) at least one polar solvent; (2) at least... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070020212 - System and method to promote proper handwashing: The present invention generally relates to systems and methods to promote proper handwashing. Specifically, it relates to systems and methods that provide feedback to the person who is washing his hands. It further relates to systems and methods for monitoring hand hygiene compliance. In a system aspect of the present... Agent: Sheppard, Mullin, Richter & Hampton LLP

20070020217 - Cosmetic composition comprising at least two emulsifying silicone elastomers: The disclosure relates to a cosmetic composition in the form of a water-in-oil emulsion comprising at least two different emulsifying silicone elastomers, the emulsifying elastomers being present in an amount of at least 3% by weight relative to the total weight of the composition. The disclosure also relates to the... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070020218 - Composition and method for the treatment of psoriasis: Disclosed are compositions for treating psoriasis. One embodiment of the present invention is a composition for treating psoriasis comprising L-lysine, glucosamine, chondroitin and methylsulfonyl methane. Another embodiment of the present invention is a method for the treatment of psoriasis comprising orally administering a composition comprising L-lysine, glucosamine, chondroitin, and methylsulfonyl... Agent: Perkins Coie LLP

20070020219 - Method for promoting hair growth: A method is provided of promoting hair growth in a subject includes applying to the skin of the subject a composition including lactoferrin in an amount effective for at least one of proliferating and activating hair follicles in the hypodermis of skin of the subject.... Agent: Akin Gump Strauss Hauer & Feld L.L.P.

20070020220 - Personal care compositions: Personal care compositions comprising a dipeptide and methods of using such compositions to treat the condition of keratinous tissue. The C terminal amino acid of said dipeptide is threonine. The personal care composition can be applied topically, ingested orally, injected, or used as part of a combined treatment regimen.... Agent: The Procter & Gamble Company Intellectual Property Division

20070020214 - Dual or multiple phase cosmetic agent with improved reversible mixing and separation behavior: The invention relates to a method for the permanent deformation of keratin fibers. According to said method, the fibers are treated with an aqueous preparation of a keratin-reducing substance prior to and/or after a mechanical deformation, then after a certain exposure time, the fibers are rinsed again with a first... Agent: Paul & Paul

20070020221 - Regulation of mammalian keratinous tissue using personal care compositions comprising cetyl pyridinium chloride: Personal care composition including a first skin and/or hair care active cetyl pyridinium chloride; and at least one additional skin and/or hair care active selected from the group consisting of tetrahydrocurcumin, sugar amine, vitamin B3, retinoids, hydroquinone, peptides, phytosterol, dialkanoyl hydroxyproline, hexamidine, salicylic acid, n-acyl amino acid compounds, sunscreen actives,... Agent: The Procter & Gamble Company Intellectual Property Division

20070020216 - Compositions for treating keratinous surfaces: A cosmetic composition comprising a hexapeptide having Sequence ID No. 1 in a cosmetically acceptable carrier, and use of such cosmetic compositions in improving skin conditions associated with aging such as winkles, fine lines, laxity, mottled pigmentation, and sallowness.... Agent: Julie Blackburn Revlon Consumer Products Corporation

20070020215 - Hair treatment method: Disclosed herein is a method for treating keratinous fibers comprising coating the keratinous fibers with a reducing agent, rinsing the keratinous fibers, coating the keratinous fibers with a cosmetic composition comprising at least one non crystalline or semi-crystalline fixing polymer, at least one cerid, and/or at least one sterid, raising... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070020223 - Air scenting compositions for spray application on air scenting devices: Aqueous compositions as well as processes and devices are disclosed for spray application on an air scenting device to provide long lasting freshening or scenting of air flowing through the device with minimal blockage of air flow through the device. The compositions contain a polymeric emulsion, a surfactant and a... Agent: James B. Raden

20070020222 - Environmental control of confined animal rearing facilities with liquid iron compounds: A system is provided for enhancing the environment in enclosed facilities for rearing livestock. The system involves the addition of a suitable amount of liquid ferric sulfate or ferric chloride a mixture thereof to bedding material or to the floor area where the livestock is confined. The concentration of the... Agent: Arthur J. Plantamura General Chemical Performance Products LLC.

20070020225 - Human placental collagen compositions, processes for their preparation, methods of their use and kits comprising the compositions: The present invention provides compositions comprising human placental collagen, methods of preparing the compositions, methods of their use and kits comprising the compositions. The compositions, kits and methods are useful, for example, for augmenting or replacing tissue of a mammal.... Agent: Jones Day

20070020226 - Polyacrylamide hydrogel for the treatment of incontinence and vesicouretal reflux: The present invention relates to a bio-stable hydrogel for use in the treatment and prevention of incontinence and vesicouretal reflux. The hydrogel is obtainable by combining acrylamide and methylene bis-acrylamide in amounts to provide about 0.5 to 25% by weight polyacrylamide, based on the total weight of the hydrogel.... Agent: Hunton & Williams LLP Intellectual Property Department

20070020224 - Protein-proteophore complexes: The application relates to a composition comprising a hyperbranched polymer attached to a core and a biologically active moiety. The biologically active moiety is attached to the core by means of a substantially non-enzymatically cleavable linker L. The composition can be used to deliver the biologically active moiety to its... Agent: Connolly Bove Lodge & Hutz, LLP

20070020227 - Use of truncated cysteine il28 and il29 mutants to treat cancers and autoimmune disorders: Methods for treating patients with cancer and autoimmune disorders using IL-28 and IL-29 molecules. The IL-28 and IL-29 molecules include polypeptides that have homology to the human IL-28 or IL-29 polypeptide sequence and proteins fused to a polypeptide with IL-28 and IL-29 functional activity. The molecules can be used as... Agent: Zymogenetics, Inc. Intellectual Property Department

20070020228 - Method of using a biosealant device: Currently used techniques for sealing impaired tissue following medical procedures are not optimal. Manual compression, though effective, is time consuming and current sealing products use animal proteins, which can cause immunological reactions and disease. Therefore, a desirable product is one that easily and effectively seals a wound in tissue without... Agent: Coats & Bennett, PLLC

20070020229 - Optimum density termite bait composition: A composition in compacted form for use for termite monitoring and control comprises a cellulose material which may be purified cellulose or micro-crystalline cellulose as a base bait, the composition being compacted to an optimum density of not less than approximately 1.033 g/cc. Also disclosed is a method for monitoring... Agent: Senniger Powers

20070020232 - Compositions and methods for cancer immunotherapy: The invention relates to immunotherapeutic compounds and to methods for stimulating an immune response in a subject individual at risk for developing cancer, diagnosed with a cancer, in treatment for cancer, or in post-therapy recovery from cancer or the compounds of the invention can be administered as a prophylactic to... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070020231 - Remedy for kidney diseases: The present invention relates to therapeutic agents for renal diseases containing a colony-stimulating factor (CSF) as an active ingredient and renal tissue repairing/regenerating agents containing a colony-stimulating factor (CSF) as an active ingredient. The colony-stimulating factor (CSF) is preferably granulocyte colony-stimulating factor (G-CSF).... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070020230 - Use of chemokines, and pharmaceutical preparations containing the same: The present invention relates to the use of chemokines and/or nucleic acids encoding a chemokine for recruiting mesenchymal precursor and/or stem cells in vivo and in vitro. The present invention also relates to pharmaceutical preparations which comprise these substances and which are preferably intended for recruiting mesenchymal precursor and/or stem... Agent: Sieberth & Patty, LLC

20070020233 - Use of il-12 and il-12 antagonists in the treatment of autoimmune diseases: Method of treating autoimmune conditions are disclosed comprising administering to a mammalian subject IL-12 or an IL-12 antagonist. In certain preferred embodiments the autoimmune condition is one which is promoted by an increase in levels of IFN-γ or TNF-α. Suitable conditions for treatment include multiple sclerosis, systemic lupus erythematosus, rheumatoid... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070020234 - Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor: Hepatocyte growth factor/scatter factor (HGF/SF), acting through the Met receptor, plays an important role in most human solid tumors and inappropriate expression of this ligand-receptor pair is often associated with poor prognosis. The molecular basis for the malignant activity imparted by signaling of HGF/SF-Met in cancer cells has been attributed... Agent: Mckenna Long & Aldridge LLP

20070020235 - Interferon-alpha polypeptides and conjugates: The present invention provides interferon-alpha polypeptides and conjugates, and nucleic acids encoding the polypeptides. The invention also includes compositions comprising these polypeptides, conjugates, and nucleic acids; cells containing or expressing the polypeptides, conjugates, and nucleic acids; methods of making the polypeptides, conjugates, and nucleic acids; and methods of using the... Agent: Maxygen, Inc. Intellectual Property Department

20070020236 - Defective sindbis viral vectors: Disclosed herein are new defective Sindbis viral vectors made from wild type Ar-339 Sindbis virus, with differences in replicase and envelope proteins between JT vectors and consensus Sindbis virus sequences, and also between JT and Ar-339 vectors. Also disclosed are plasmids used for the production of the vectors, methods for... Agent: Darby & Darby P.C.

20070020237 - Glucose inducible insulin expression and methods of treating diabetes: The invention provides an isolated tissue specific glucose responsive promoter having a polymerase binding domain 3′ to at least one tripartite transcription factor binding cis element having a hepatocyte nuclear factor-1 (HNF-1) element, a CAAT/enhancer binding protein (C/EBP) response element and a glucose-response element (GRE). The promoter can include a... Agent: Mcdermott Will & Emery LLP Attn: Intellectual Property Deptartment

20070020239 - Heximi as a suppressor of hiv replication and cardiac hypertrophy: Cellular transcription is modulated by increasing or decreasing the amount of active HEXIM1 in the cell. The methods are applied to the treatment of HIV infection and cardiac hypertrophy. Assays using reconstituted 7SK:P-TEFb snRNP screen for agents that modulate HEXIM1-P-TEFb binding.... Agent: Richard Aron Osman Science And Technology Law Group

20070020238 - Method of targeted gene delivery using viral vectors: Methods and compositions are provided for delivering a polynucleotide encoding a gene of interest to a target cell using a virus. The virus envelope comprises a cell-specific binding determinant that recognizes and binds to a component on the target cell surface, leading to endocytosis of the virus. A separate fusogenic... Agent: Knobbe Martens Olson & Bear LLP

20070020248 - Process for biological tissue: The present invention provides an electrophoretic system, apparatus, and method of use thereof for the preparation of a tissue-derived bioprosthesis.... Agent: Katharine A. Jackson Huebsch Medtronic, Inc.

20070020249 - Compositions for prevention and treatement of symptoms of gastrointestinal distress: A composition for the treatment or prevention of gastro-intestinal distress associates with the consumption of food products containing sugar alcohols includes at least one enzyme, at least one probiotic organism and simethicone. The composition may be consumed immediately prior to but not more than 20 minutes prior to consuming a... Agent: Pauley Petersen & Erickson

20070020250 - Lactic acid bacteria producing nisin at high concentration and method for selecting the same: The present invention provides lactic acid bacteria producing Nisin, a method for selecting the same, and foods or feeds using the lactic acid bacteria.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070020240 - Defined dose therapeutic phage: The invention provides therapeutic, defined-dose anti-bacterial phage preparations, methods to make such preparations, methods to treat bacterial infections using such preparations and methods to diagnose bacterial infections using such preparations.... Agent: Townsend And Townsend And Crew, LLP

20070020241 - Use of photosensitisation: A composition comprising a conjugate of a photosensitiser and a bacteriophage is provided. The conjugate may be used to kill bacteria, particularly MRSA, EMRSA, VRSA, hetero-VRSA or CA-MRSA in a targeted method of photodynamic therapy.... Agent: Nixon & Vanderhye, PC

20070020245 - Composition for the treatment of arthrosis/arthritis, especially for treating joints: The invention especially relates to a composition for the treatment of arthrosis/arthritis, especially for treating joints, said composition containing at least one carrier substance for receiving at least one anti-inflammatory agent and chondrogenetic cells, in addition to at least one anti-inflammatory agent, and chondrogenetic cells.... Agent: Shlesinger, Arkwright & Garvey LLP

20070020247 - Dopaminergic neurons derived from corneal limbus, methods of isolation and uses thereof: The present disclosure describes the generation of neural cells and neurons from mammalian pluripotent embryonic-like stem cells (ELSCs) isolated from corneal limbal tissue, a non-embryonic tissue. Specifically, the present disclosure describes the generation of neuroprogenitor cells and differentiated dopaminergic neurons from ELSCs. The disclosed methods demonstrate the potential of ELSCs... Agent: Vinson & Elkins, L.L.P.

20070020244 - Fiber constructs and process of fiber fabrication: Described herein are fiber compositions, methods of generating the fiber compositions, and methods of using the fiber compositions in various applications utilizing fiber constructs, including for example, tissue engineering.... Agent: Edwards Angell Palmer & Dodge LLP

20070020242 - Method for transdifferentiation of non-pancreatic stem cells to the pancreatic pathway: The subject invention relates to a method of transdifferentiating mammalian non-pancreatic stem cells, such a mesenchymal stem cells (MSCs), to enter the pancreatic differentiation pathway. The MSCs are cultured under conditions that permit the expression of pancreatic differentiation markers, and these conditions include use of: (a) culture conditions that promote... Agent: Swanson & Bratschun L.L.C.

20070020243 - Methods and compositions related to modulating the extracellular stem cell environment: This invention relates, in part, to methods and compositions that modulate the stem cell environment. More specifically, the invention relates, in part, to methods and compositions for modulating stem cell differentiation. Such modulation, in some aspects of the invention, is accomplished by agents that modulate glycosaminoglycans in the stem cell... Agent: Wolf Greenfield & Sacks, PC

20070020246 - Use of microchimeric cells in the treatment of malignancy: Methods and formulations for the treatment of malignancies. Assessment of the incidence and scope of MC in control and cancer populations provides for the development of cellular therapy approaches to hematologic malignancies that are expected to be well tolerated immunologically. Studies will confirm that parous females who display MC are... Agent: James G. Dilmore, Ph.d. Reed Smith LLP

20070020251 - Paralytic peptide for use in neuromuscular therapy: The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.... Agent: Synnestvedt & Lechner, LLP

20070020252 - Modified protease inhibitors: DX-890 inhibits elastase. DX-890 can be attached a single polyethylene glycol moiety. The polyethylene glycol is at least 18 kDa in molecular weight and is attached to the polypeptide by a single covalent bond to the N-terminus of the polypeptide.... Agent: Fish & Richardson PC

20070020253 - Spleen tyrosine kinase catalytic domain:crystal structure and binding pockets thereof: The present invention provides crystalline molecules and molecular complexes that comprise binding pockets of Sykcat and its homologues. The invention also provides crystals comprising the catalytic domain of Syk protein. The invention further provides a computer comprising a data storage medium encoded with the structure coordinates of Sykcat binding pockets... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070020254 - Methods and compositions for treatment of inflammatory disease: Compositions useful for treating inflammatory diseases including arthritis are disclosed which comprise cetyl myristoleate compounds or related compounds and at least one compound useful for treatment of inflammatory disease, such as tetracycline compounds, Cox-2 inhibitors, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, local anaesthetics, chelating agents, matrix metalloprotease inhibitors, inhibitors of inflammatory... Agent: Kenyon & Kenyon LLP

20070020255 - Method of stabilizing antibody and stabilized solution-type antibody preparation: The present invention provides a method of suppressing the formation of a soluble association of an antibody in a solution; a method of suppressing the formation of a chemically degraded product of an antibody in a solution; and a method of stabilizing an antibody in a solution. The present invention... Agent: Fitzpatrick Cella Harper & Scinto

20070020256 - Methods for treatment of allergic asthma: Methods of treatment of allergic asthma with IgE antagonists, including anti-IgE antibodies, IgE variants, peptide antagonists, peptidomimetics and other small molecules, are described.... Agent: Genentech, Inc.

20070020259 - Anti-cd20 antibodies and fusion proteins thereof and methods of use: The present invention provides humanized, chimeric and human anti-CD20 antibodies and CD 20 antibody fusion proteins that bind to a human B cell marker, referred to as CD20, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases, and methods of treatment... Agent: Rossi, Kimms & Mcdowell LLP.

20070020260 - Glycoprotein compositions: The present invention concerns compositions comprising a glycoprotein having an Fc region, wherein about 80-100% of the glycoprotein in the composition comprises a mature core carbohydrate structure which lacks fucose, attached to the Fc region of the glycoprotein. The preferred glycoprotein is an antibody or immunoadhesin.... Agent: Genentech, Inc.

20070020258 - Immunoglobulin variants: The present invention describes IgE antagonists (including variant anti-IgE antibodies) and their use in diagnosis, therapy or prophylaxis of allergic and other IgE-mediated disorders, including asthma, food allergies, hypersensitivity and anaphylactic reactions.... Agent: Genentech, Inc.

20070020257 - Polypeptide: The present invention provides a polypeptide inducing the production of an antibody in permucosal administration in the presence of no immunological adjuvant, a composition containing the polypeptide, and use thereof. The present invention solves the above object by providing a polypeptide inserted with a cell attachment motif of a cell... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070020261 - Combination therapy of her expressing tumors: The invention relates to tumors expressing HER2 and EGFR, using HER2-dimerization inhibitors (HDIs) and EGFR inhibitors.... Agent: Heller Ehrman LLP

20070020262 - Uses of mammalian cytokine: related reagents: Provided are methods of modulating dendritic cell activity using agonists or antagonists of a mammalian cytokine. Also provided are methods of treating immune disorders.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070020265 - Immunotherapy of autoimmune disorders using antibodies which target b-cells: Antibodies that bind with a B-cell antigen provide an effective means to treat autoinmune disorders. Antibodies and fragments, which may be conjugated or naked, are used alone or in multimodal therapies. The antibodies may be bispecific antibodies which may be produced recombinantly as fusion proteins, or as hybrid, polyspecific antibodies.... Agent: Rossi, Kimms & Mcdowell LLP.

20070020263 - Medicine containing genetically modified antibody against chemokine receptor ccr4: A medicament having a higher therapeutic effect than that provided by administration of a recombinant antibody against human CC chemokine receptor 4 or an antibody fragment thereof or an agent alone is provided.... Agent: Fitzpatrick Cella Harper & Scinto

20070020264 - Serum albumin binding peptides for tumor targeting: Peptide ligands having affinity for serum albumin are useful for tumor targeting. Conjugate molecules comprising a serum albumin binding peptide fused to a biologically active molecule demonstrate modified pharmacokinetic properties as compared with the biologically active molecule alone, including tissue (e.g., tumor) uptake, infiltration, and diffusion.... Agent: Genentech, Inc.

20070020267 - Anti-vegf antibodies: Anti-VEGF antibodies and variants thereof, including those having high affinity for binding to VEGF, are disclosed. Also provided are methods of using phage display technology with naïve libraries to generate and select the anti-VEGF antibodies with desired binding and other biological activities. Further contemplated are uses of the antibodies in... Agent: Merchant & Gould PC

20070020266 - Gpr54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases: The invention provides an agonist or antagonist of the GPR54 receptor for its use for treating a gonadotropin related disorder, a ligand of the GPR54 receptor for its use for diagnosing a subject's gonadotropin abnormality; a method for screening a compound that affect the gonadotropic axis comprising the step of... Agent: Stattler, Johansen, And Adeli LLP

20070020268 - Treatment of inflammatory bowel disease with ifn-gamma inhibitors: The invention concerns a method for the prevention or treatment of inflammatory bowel disease by administering an interferon-γ inhibitor. The invention further concerns pharmaceutical compositions and bispecific molecules useful in such method.... Agent: Merchant & Gould PC

20070020270 - Human serpin polypeptides: This invention relates to Thypin, a new member of the human serpin polypeptide family, methods of making Thypin polypeptides and using these polypeptides to treat various medical disorders and to methods of screening for compounds that agonize or antagonize Thypin polypeptide activities.... Agent: Immunex Corporation Law Department

20070020269 - Phosphokinase and the usage thereof: The present invention relates to a novel phosphokinase, RX50 protein, polynucleotide encoding RX50 protein and the recombinant method of producing the same. RX50 protein can interact with p21 and cyclin D3, and inhibit the transcription of p53. Therefore, it can be used as a drug target for new drug selection.... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070020278 - Diagnosing and treating cancer: Methods for treating or diagnosing cancers of the female reproductive tract and childhood cancers are disclosed. The methods described herein use binding agents, e.g., antibodies, specific for the extracellular domain of human prostate specific membrane antigen (PSMA).... Agent: Fish & Richardson PC

20070020271 - Endothelial cell specific antibodies and uses thereof: Methods and composition provided herein relate to the inhibition of proliferation, migration, and tubule formation of cells and are thus useful in treating angiogenesis associated diseases, including cancer, polycystic kidney disease, diabetic retinopathy, rheumatoid arthritis, and psoriasis. Disclosed are methods of inhibiting endothelial cell proliferation, migration, and tubule formation by... Agent: Morrison & Foerster LLP

20070020277 - Human oncogene induced secreted protein i: The present invention relates to a novel protein, the Human Oncogene Induced Secreted Protein I (“HOIPS I”) protein. In particular, isolated nucleic acid molecules are provided encoding the human HOIPS I protein. HOIPS I polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same.... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070020272 - Indirectly linked photosensitizer immunoconjugates, processes for the production thereof and methods of use thereof: The present invention relates to indirectly linked photosensitizer immunoconjugate (PIC) compositions, methods of preparation and the use of the same in photodynamic therapeutic and diagnostic applications. PICs comprising a photosensitizer indirectly linked to an antibody via a PEGylated polyglutamate chain are described.... Agent: Edwards & Angell, LLP

20070020274 - Method of preventing or reducing the likelihood of pregnancy: The present invention relates to compositions and methods for reducing the likelihood that a woman will become pregnant or that an unwanted pregnancy may be terminated by administering an inhibitor of H-hCG or β-H-hCG to said a woman at risk to become pregnant. Methods of enhancing the likelihood that a... Agent: Coleman Sudol Sapone, P.C.

20070020276 - Methods for the treatment of carcinoma: The invention concerns compositions and methods for the diagnosis and treatment of neoplastic cell growth and proliferation in mammals, including humans. The invention is based upon the identification of genes that are amplified in the genome of tumor cells, such as renal cell carcinoma. Such gene amplification is expected to... Agent: Genentech, Inc.

20070020275 - Nucleic acid sequences of hyperplasia and tumours of the thyroid: The invention relates to a nucleic acid which codes for a polypeptide. Said polypeptide comprises a KRAB domain and/or at least one zinc finger motif, whereby the KRAB domain contains the amino acid sequence of SEQ ID NO: 1 and the zinc finger motif is of the type contained in... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070020273 - Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.... Agent: S2iplaw, PLLC

20070020279 - Human-murine chimeric antibodies against respiratory syncytial virus: This invention relates to a human antibody which contains the one CDR from each variable heavy and variable light chain of at least one murine monoclonal antibody, against respiratory syncytial virus which is MAb 1129 and the use thereof for the prevention and/or treatment of RSV infection.... Agent: Johnathan Klein-evans

20070020280 - Compositions and methods for inhibition of hiv-1 infection: This invention provides a composition which comprises an admixture of three compounds, wherein: (a) one compound is an antibody which binds to a CCR5 receptor; (b) one compound retards attachment of HIV-1 to a CD4+ cell by retarding binding of HIV-1 gp120 envelope glycoprotein to CD4 on the surface of... Agent: Cooper & Dunham, LLP

20070020281 - Monoclonal antibodies specific for anthrax spores and peptides derived from the antibodies thereof: The present invention relates to peptides that bind to the bacterial spores, such as B. anthracis, B. subtilis and B. cereus spores. The present invention also relates to method of identifying such peptides using phage display ligand screening system. The present invention further relates to the use of such peptides... Agent: Dla Piper US LLP Attn: Patent Group

20070020282 - Immunstimulating lipid formulation: A pharmaceutical formulation for parenteral or mucosal administration of antigens and/or vaccines to humans and animals, comprising monglyceride preparations having at least 80% monoglyceride content and where the acyl group contains from 6 to 24 carbon atoms, together with fatty acids where the number of carbon atoms may be varied... Agent: Bacon & Thomas, PLLC

20070020283 - Interferon-gamma antagonists and therapeutic uses thereof: Polypeptides and multimeric polypeptides capable of binding interferon γ which are useful therapeutically in methods of treating interferon γ-related conditions or diseases.... Agent: Regeneron Pharmaceuticals, Inc

20070020284 - Ob fusion protein compositions and methods: The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or... Agent: Molly Holman, Esq. Amylin Pharmaceuticals, Inc.

20070020285 - Novel peptide compositions and the use thereof, in particular, in the preparation of active pharmaceutical compositions against the hepatitis c virus: The invention relates to novel peptide compositions. In particular, the invention relates to a peptide composition comprising at least two peptides which are selected from among the following peptides: a peptide A having at least the amino acid sequence of SEQ ID N° 1, a peptide B having at least... Agent: Clark & Elbing LLP

20070020286 - Recombinant constructs of borrelia burgdorferi: Novel chimeric nucleic acids, encoding chimeric Borrelia proteins comprising OspC or an antigenic fragment thereof and OspA or an antigenic fragment thereof, are disclosed. Chimeric proteins encoded by the nucleic acid sequences are also disclosed. The chimeric proteins are useful as vaccine immunogens against Lyme borreliosis, as well as for... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070020287 - Virulence genes of m.marinum and m. tuberculosis: Methods for identifying, isolating and mutagenizing virulence genes of mycobacteria, e.g., M. marinum and M. tuberculosis, are described. Also described are isolated virulence genes and fragments of them, isolated gene products and fragments of them, avirulent bacteria in which one or more virulence genes are mutagenized, attenuated vaccines containing such... Agent: Millen, White, Zelano & Branigan, P.C.

20070020290 - Natural antibodieactive against hiv virus: A preparation of human antibodies capable of neutralizing HIV-1 virus and the use thereof in the treatment of HIV infection.... Agent: Young & Thompson

20070020289 - Preparations and processes for stabilizing biological materials by means of drying processes without freezing: The present invention concerns processes for the production of dry, partially amorphous products containing biologically active and in particular therapeutically active material which are macroscopically homogeneous substance mixtures, the substance mixtures being selected from at least one substance of each of the groups (i) carbohydrate or zwitterion with a polar... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070020288 - Vaccine: This invention pertains to methods for treating infections caused by human papillomaviruses. It has been determined that immunization with HPV 16 and HPV 18 virus like particles provides cross-protection against other HPV types.... Agent: Glaxosmithkline Corporate Intellectual Property - Uw2220

20070020291 - Vaccines for protection from bartonella infection and related methods of use: Embodiments of the present invention generally comprise vaccines for substantially inhibiting or preventing infection from Bartonalla and related methods of vaccination.... Agent: Intervet Inc. Patent Department

20070020292 - Novel method for isolating endotoxins: The invention concerns a novel method for extracting endotoxins from bacteria, and the use of said method for preparing compositions comprising endotoxins or derivatives thereof designed for human or animal use (scientific, medical usage).... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070020293 - Vaccines against group neisseria meningitidis and meningococcal combinations thereof: This invention relates to modified meningococcal Y polysaccharides (GYMP), conjugates comprising the modified polysaccharides and a carrier, vaccines for the immunisation of warm-blooded animals, including humans, against Group Y Neisseria meningitidis, and to methods for producing these modified polysaccharides, conjugates and vaccines.... Agent: Morgan & Finnegan, L.L.P.

20070020295 - Controlled release neurotoxin system and method: A botulinum toxin system for in vivo release of therapeutic amounts of botulinum toxin in a human patient over a prolonged period of time.... Agent: Allergan, Inc.

20070020294 - Use of botulinum toxin for treatment of articular pathologies: Use of botulinum toxin to obtain a product intended to be administered intramuscular with lissive effect in treating articular pathologies, particularly coxarthrosis, or arthrosis of the hip, epicondylitis of the elbow and rotator muscle cap pathology of the shoulder.... Agent: Stevens Davis Miller & Mosher, LLP

20070020296 - Mycoplasma hyopneumoniae bacterin vaccine: The invention provides an improved Mycoplasma hyopneumoniae bacterin vaccine composition, which advantageously provides immunity from infection after a single administration. The composition comprises an inactivated Mycoplasma hyopneumoniae bacterin and an adjuvant mixture, which, in combination, provide immunity from Mycoplasma hyopneumoniae infection after a single administration, and elicit an immune response... Agent: Wyeth Patent Law Group

20070020297 - System and method for the treatment of cancer, including cancers of the central nervous system: The invention relates to the treatment of cancer, and particularly to the treatment of cancers of the central nervous system, such as glioblastoma multiforme. A dual therapeutic approach is provided, including the administration of a dendritic cell-based cancer vaccine and a regimen of chemotherapy. The two therapies may be administered... Agent: Davis Wright Tremaine LLP

20070020299 - Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid: An inhalable formulation containing SAE-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use... Agent: Innovar, LLC

20070020298 - Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid: An inhalable formulation containing SAE-γ-CD and corticosteroid is provided. The formulation is adapted for administration to a subject by nebulization with any known nebulizer. The formulation can be included in a kit. The formulation is administered as an aqueous solution, however, it can be stored as a dry powder, ready-to-use... Agent: Innovar, LLC

20070020300 - Recreational water treatment employing singlet oxygen: Recreational or process water can be treated by uniformly dissolving in the water a singlet oxygen-generating photosensitizer selected from the group consisting of condensed aromatic compounds, acridine dyes, coumarin dyes, crystal violet, fluorene derivatives, porphyrin derivatives, chlorins, thiazine dyes, thioketones, xanthene dyes, or by uniformly dissolving in the water a... Agent: Iplm Group, P.A.

20070020301 - Beautification method: It is intended to provide a cosmetic method that comprises carrying out a beauty treatment in exact timing with an increase in the concentration of a medicinal component that has been taken in blood so as to establish a favorable cosmetic effect owing to synergy of both. A subject person... Agent: Knobbe Martens Olson & Bear LLP

20070020302 - Exfoliating cream: An exfoliating cream and method of forming. The cream includes particles of a stone. The stone may be a precious or semi-precious stone of a characteristic color. The cream appears to be the color of the characteristic color. The cream may also include coloring agents to impart the characteristic color.... Agent: Crowell & Moring LLP Intellectual Property Group

20070020303 - Crow repelling cloth: In order to provide a crow repelling cloth for keeping off crows at a low cost, a cloth is impregnated with calcined fine powder of highly pure silica-titanium together with a resin so as to release minus ions. The cloth is colored in yellow or black. The cloth can be... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070020304 - Non-flammable insecticide composition and uses thereof: The present invention provides a safe and effective insecticide composition suitable for treating a subject infested with a parasitic anthropode or to prevent infestation by an arthropod. The insecticide composition is a foamable composition, including a first insecticide; at least one organic carrier selected from a hydrophobic organic carrier, a... Agent: Wilmer Cutler Pickering Hale And Dorr LLP

20070020305 - Attractant for monitoring or controlling female stored product moths: A lure for attracting females of stored product moths comprising an cold hexane extract or a synthetic equivalent of an oily seed. The extract or equivalent comprises material such as single-chain or branched, saturated or unsaturated hydrocarbons, alcohols, aldehydes, and ketones. The extract includes extracts of nuts, chick starter and... Agent: Fellers Snider Blankenship Bailey & Tippens

20070020306 - Endovascular implant with an at least sectional active coating made of radjadone and/or a ratjadone derivative: An endovascular implant, comprising an at least sectional active coating (8) in which a (re)stenosis-inhibiting substance (10) based on a ratjadone derivative is embedded.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070020307 - Medical devices containing radiation resistant polymers: The present invention relates generally to radiation-resistant medical devices which contain polymer regions for release of therapeutic agents. The present invention also relates to radiation-resistant copolymer materials for use in connection with insertable or implantable medical devices. The radiation-sterilized medical device comprises (a) a release region and (b) at least... Agent: Mayer & Williams PC

20070020308 - Polymers having covalently bound therapeutic agents: Therapeutic polymers are described, which contain at least one polymeric portion and at least one therapeutic agent. The therapeutic agent and the polymeric portion are covalently linked via one or more linkages which hydrolyze in an aqueous environment, for example, one or more linkages selected from an Si—N linkage, an... Agent: Mayer & Williams PC

20070020309 - Safe and effective biofilm inhibitory compounds and health related uses thereof: The present invention provides compounds and materials that reduce the accumulation of microorganisms a surface, by interfering with the attachment of the organisms to the surface. The compounds and materials are thus useful in preventing the formation of biofilms on surfaces in health-related environments. By preventing the formation of biofilms,... Agent: Foley Hoag, LLP Patent Group, World Trade Center West

20070020310 - Self-assembled, micropatterned, and radio frequency (rf) shielded biocontainers: The present invention relates to a nanoscale or microscale container for encapsulation and delivery of materials or substances, including, but not limited to, cells, drugs, tissue, gels and polymers contained within the container, with subsequent release of the therapeutic materials in situ, methods of fabricating the container by folding a... Agent: Patent Docket Administrator Lowenstein Sandler PC

20070020311 - Medicament delivery device and a method of medicament delivery: A medicament delivery device and method of delivery a medicament is provided wherein the device is insertable into the uterine myometrium for the delivery of medicaments to the pelvic area and organs thereof, for example, the bladder, peritoneum, the vulva, vagina, fallopian tubes, ovaries and uterus and then to the... Agent: Drinker Biddle & Reath Attn: Intellectual Property Group

20070020312 - Method of fabricating a bioactive agent-releasing implantable medical device: The present invention relates to methods of controlling the loading of a bioactive agent into a polymeric carrier to be coated on an implantable medical device to achieve controlled release of the bioactive agent.... Agent: Squire, Sanders & Dempsey LLP

20070020313 - Composition of amylase inhibitors and fibers to reduce the absorption of starch in human digestion from starchy foods, and to reduce the glycemic index of starchy foods: A composition of amylase inhibitors and fibers to reduce the absorption of starch in human digestion from starch-containing foods, and to reduce the glycemic index of starch containing foods.... Agent: Daniel Maiullo

20070020314 - Adhesion inhibiting material for vertebral/spinal operation: It is to provide a material to inhibit spine/spinal cord adhesion in the form of a sponge, a film or a suspension to be used for the purpose of assisting/accelerating the tissue healing. An adhesion inhibiting material for a spine/spinal cord surgery in the form of a sponge, a film... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070020317 - Negative ionic silica gel composition and the process for producing the same: The present invention relates to a negative ionic silica gel composition and the method of manufacturing the same. The composition includes negative ionic powder and silica gel. The negative ionic silica gel can be used to manufacture various suitable products or coat the surfaces of the products thereby adding the... Agent: Stephen E. Feldman, P.C.

20070020316 - Personal topical disinfectant device: A personal topical disinfectant device, including a pair of the flexible, fluid-impermeable sheets joined at their peripheries to establish a fluid-tight central region in closing a folded flexible sheet impregnated with and ingestible antibacterial agent. Optionally, the flexible sheet is impregnated with a flavoring and/or texturizing agent.... Agent: Greenberg Traurig, LLP

20070020315 - Tissue products having low stiffness and antimicrobial activity: The inner plies of a multi-ply antimicrobial tissue product are selectively weakened by chemical or mechanical means to improve the overall softness of the tissue product. The addition of a deliquescent salt to the inner ply or plies containing the antimicrobial agent is particularly advantageous.... Agent: Kimberly-clark Worldwide, Inc.

20070020319 - Adhesive composition: The invention relates to an adhesive composition comprising hydrophilic silicone elastomers and hydrophobic silicone elastomers and optionally water absorbent material, wherein the ratio between the hydrophilic silicone elastomers and the hydrophobic silicone elastomers is from 95:5 to 5:95. The adhesive is suited for medical use due to its skin-friendliness. The... Agent: Jacobson Holman PLLC

20070020318 - Hydrocolloid materials for use in wound healing: A wound dressing material comprising a low-moisture hydrocolloid matrix having oxidized cellulose distributed therein. For example, a matrix of dried sodium carboxymethylcellulose gel having fibers of oxidized regenerated cellulose dispersed therein. Also provided are the use of such materials in the treatment of wounds, and the manufacture of such materials... Agent: Philip S. Johnson Johnson & Johnson

20070020320 - Wound dressing and methods of making and using the same: Anti-microbial wound dressings, methods of making anti-microbial wound dressings and methods of treating wounds with an anti-microbial wound dressing are provided. The anti-microbial wound dressings can include a water-soluble film-forming polymeric carrier material and a water-soluble glass-encapsulated anti-microbial agent, which is embedded within the carrier and/or coated on a surface... Agent: Tyco Healthcare Group Lp

20070020321 - Method for enhancing attenuation characteristic of absorbent materials useful with dermal and transdermal substance delivery systems: A method for preparing a patch containing at least one substance to be delivered into a user, the method including: providing an absorbent material; introducing the at least one substance into the material; placing the material inside the patch; and, sealing the substance holding material containing patch. The absorbent material... Agent: Plevy & Howard, P.C.

20070020325 - Hydrogel composition: A hydrogel composition containing as an active ingredient a drug that is transdermally or transmucosally absorbed to produce a drug effect, the hydrogel composition comprising polyvinyl alcohol with a saponification degree of 90-96 mol %, a water-soluble polymer and water, wherein the content of the water-soluble polymer is no greater... Agent: Fitch, Even, Tabin & Flannery

20070020323 - Method and device for improving the permeability of the human skin: The invention relates to a method for improving the permeability of the human skin in order to transdermally supply active substances, permeability being improved by means of a plaster that is transparent in at least some areas, contains active sub-stance, and is flexible in at least some areas, and at... Agent: William F. Lawrence Frommer Lawrence & Haug

20070020324 - Method and device to treat skin affected by a corn: A method of treating skin affected by a corn comprising applying a non-acidic healing compound to the skin, and applying silicone or other occlusive material to the skin. The non-acidic healing compound and occlusive material may be in the form of layers. The method may be in the form of... Agent: Barnes & Thornburg LLP

20070020322 - Method for inhibiting the growth of antibiotic resistant of bacteria by using pentane-1, 5-diol: A method for inhibiting the growth of multiple-resistant bacteria comprises the topical administration of a pharmaceutical composition comprising 15% by weight or more of pentane-1,5-diol and a pharmaceutical acceptable carrier. Also disclosed is a method of preparing a corresponding medicament. A method of disinfecting a surface contaminated with multiple-resistant bacteria... Agent: Dickstein Shapiro LLP

20070020326 - Drug delivery system and method: A method for delivering a therapeutic agent to a predetermined location in a host is disclosed, wherein a liposome-encapsulated therapeutic agent is administered to the host, and an electrical field which encompasses a predetermined region within the host is established, such that as the liposome-encapsulated agent is exposed to the... Agent: James C Weseman Law Offices Of James C Weseman

20070020327 - Inducing cellular immune responses to prostate cancer antigens using peptide and nucleic acid compositions: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare prostate cancer-associated antigen epitopes, and to develop epitope-based vaccines directed towards prostate tumors. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070020328 - Probiotics as alternative medicines against infectious diseases: An exemplary embodiment providing one or more improvements includes feeding animals with probiotic microbes encapsulated in a mixture of xanthan gum and chitosan, or in gelatin, specifically Pediococcus acidilactici and Saccharomyces boulardii. Such encapsulation protects the viability of the probiotic microbes against unfavorable temperatures. An exemplary embodiment providing one or... Agent: William S Ramsey, Esq

20070020331 - Coated tablet with zero-order of near zero-order release kinetics: Tablets for the controlled release of an active ingredient in a zero-order or near zero-order fashion are provided. The tablet includes a core and a coating. The core includes at least one active pharmaceutical agent and a polyethylene oxide with a molecular weight of between about 1,000,000 and 10,000,000, preferably... Agent: Womble Carlyle Sandridge & Rice, PLLC

20070020330 - Compositions comprising azelastine and methods of use thereof: The present invention provides pharmaceutical compositions comprising azelastine, or a pharmaceutically acceptable salt or ester thereof including azelastine hydrochloride, and optionally one or more additional active agents. Preferred such compositions further comprise one or more pharmaceutically acceptable carriers or excipients that reduce the amount of post-nasal drip, and/or that minimize... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070020329 - Methods of formulating linezolid: A method of formulating linezolid to provide a pharmaceutical composition comprising linezolid wherein the linezolid is linezolid Form IV substantially free of linezolid Form II, a solid pharmaceutical composition comprising linezolid Form IV substantially free of linezolid Form II and povidone, methods of treating a condition responsive to linezolid in... Agent: Kenyon & Kenyon LLP

20070020332 - Tannate compositions, methods of making and methods of use: Tannate compositions containing active pharmaceutical ingredients to be used for treating nausea, vomiting, pain, convulsions, and insomnia and manufacturing processes for preparing the tannate compositions.... Agent: Marla J. Church, Esq. Kiel Laboratories, Inc.

20070020333 - Controlled release of hypnotic agents: The application relates to the controlled release of a hypnotic agent with extended release profiles. The pharmaceutical composition and processes for manufacturing, and methods of using the controlled release formulation are provided.... Agent: Shihong Nicolaou

20070020334 - Benzimidazole formulation: A dry manufacturing process for the production of a pharmaceutical formulation of a benzimidazole and an alkaline substance is described. A tablet is compressed directly from a dry powder or a dry particulate matter avoiding any liquid or excipient conventionally used as a wet binder. The manufacturing process has the... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070020336 - Cyclodextrin nanotechnology for ophthalmic drug delivery: The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of... Agent: Buchanan, Ingersoll & Rooney PC

20070020335 - Sustained release pharmaceutical compositions for highly water soluble drugs: The present invention provides pharmaceutical compositions for controlled release of pharmaceutically active agents, especially those with a high water solubility, high dose, and/or short half-life. In addition, the present application provides methods for preparing and using such pharmaceutical compositions.... Agent: Seed Intellectual Property Law Group PLLC

20070020337 - Paclitaxel-based antitumor formulation: Antitumor formulation based on nanoparticles of paclitaxel and human serum albumin as obtained by the addition of a biocompatible acid to an aqueous albumin solution before this is mixed with paclitaxel during the nanoparticle production process, the injectable solutions of this formulation having a pH between 5.4 and 5.8 and... Agent: Morrison & Foerster LLP

20070020339 - Compositions and methods for controlling abuse of medications: Pharmaceutical dosage forms are provided for use in deterring abuse of opioids or other medications, which help avoid harm to a patient dependent on the medication. In one case, a pharmaceutical oral dosage form is provided that includes a plurality of microcapsules, each microcapsule of the plurality containing an opioid... Agent: Sutherland Asbill & Brennan LLP

20070020338 - Fluid bed granulation process and apparatus: A process for obtaining finished granules of a predetermined substance in a granulation fluid bed (F1) of the so-called vertical growth type, the bed being formed and maintained by a respective flow of fluidification air, comprises a transfer phase by falling of the finished granules in a pressurized space below... Agent: Akerman Senterfitt

20070020340 - Fish oil products for reducing cholesterol, low density lipoprotein, and hypertension: A composition containing EPA and EHA, preferably derived from fish oil, in combination with at least one of oleuropein, allicin, and policosanol having anti-inflammatory, anti-thrombotic, immunomodulatory activity as well as activity to lower triglycerides and low density lipoprotein, to increase high density lipoprotein, and to lower both systolic and diastolic... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070020341 - Method for preparing peritoneal dialysate: Carbonyl compounds generated and accumulated in the peritoneal dialysate can be inactivated or eliminated by a carbonyl compound-trapping agent such as aminoguanidine. Carbonyl compounds generated during sterilization and storage of the peritoneal dialysate can be eliminated by pre-contacting with the trapping agent. Further, it is possible to eliminate carbonyl compounds... Agent: Bozicevic, Field & Francis LLP

20070020342 - Non-irritating compositions containing zinc salts: The present invention relates to methods and compositions which employ low concentrations of combinations of zinc salts to prevent the irritation of skin or mucous membranes that may be caused by therapeutic agents, by personal hygiene products, by articles such as gloves or condoms, or by various physical, chemical, mechanical,... Agent: Baker & Botts L.L.P.

20070020343 - Nutrient supplements and methods for treating autism and for preventing the onset of autism: Provided by the present invention are novel and non-obvious nutrient supplements that preferably comprise minerals, vitamins, amino acids, and agents capable of delivering cysteine in vivo. The nutrient supplements desirably are capable of promoting metallothioneins, and optionally, promoting the removal of excess metals from the bloodstream. Also provided by the... Agent: Merchant & Gould PC

20070020347 - Bioavailability enhancing activity of carum carvi extracts and fractions thereof: The present invention relates to the use of extracts of Carum carvi as bioenhancers, either alone or in combination with piperine or Zinzeber officinale extract to improve the bioavailability of a wide variety of drugs.... Agent: Ladas & Parry

20070020346 - Botanical anticancer formulations: This invention relates to a method of preparing a Schizandra, Trichosanthes, Glycine, or Yucca extract. Also disclosed are compositions containing at least two of these extracts, and methods of using the compositions for inducing apoptosis or cell cycle arrest and inhibiting angiogenesis or tumor cell metastasis.... Agent: Fish & Richardson PC

20070020344 - On-growth inhibiting compounds: An on-growth inhibiting agent, for the inhibition and/or prevention of on-growth of biological organisms on objects or living beings, includes at least one cyclotide, and a suitable carrier medium. A plant extract containing a mixture of cyclotides is also usable.... Agent: Young & Thompson

20070020345 - Schisandrin b preparation: The present invention provides a preparation for treatment or prevention of a condition in a patient, said preparation comprising Schisandrin B. The concentration of Schisandrin B in the preparation may be between about 0.01 and about 0.1%, or it may be between about 20 and about 40% w/w or w/v.... Agent: Troutman Sanders LLP

20070020348 - Composition for treating hepatitis c: By administering a composition comprising pumpkin seed, safflower, plantain and honeysuckle, subjective symptoms (for example, general malaise and abdominal swelling) of a patient with chronic hepatitis C can be eliminated and, moreover, objective symptoms diagnosed by a medical doctor (for example, liver enlargement and palm erythema) can be relieved or... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070020349 - Combinations of vasoactive agents, their use in the pharmaceutical and cosmetic field, and formulations containing them: This invention relates to combinations of vasoactive substances which act at venous or arterial level with phosphodiesterase inhibitors including phosphodiesterase V, in particular: visnadin or esculoside; at least one compound selected from icarin or derivatives thereof or extracts containing it, Gingko biloba dimeric flavones either in the free form or... Agent: Young & Thompson

20070020350 - Vegetation water composition for treatment of inflammatory skin conditions: Compositions obtained from vegetation water from olives and methods for treating patients suffering from an inflammatory skin disease with the compositions are described. Included are hydroxytyrosol rich compounds obtained from olive vegetation water.... Agent: Perkins Coie LLP

20070020351 - Antitubercular extracts of salicornia brachiata: The present invention relates to enhancement of anti-tubercular activity of active fraction isolated from Salicornia brachiata. The invention also discloses the non-toxic nature of the fraction and positively identifies Sucrose as its main constituent. Pure Sucrose is shown to have no anti-tubercular activity indicating thereby that activity of the fraction... Agent: Nixon & Vanderhye, PC

20070020352 - Treatment modalities for autoimmune diseases: Compositions of reduced isoalpha acids, vitamins and minerals are disclosed as well as methods of using the same for the treatment of autoimmune diseases. Additional combinations including other compounds are also contemplated. Synergistic properties and methods exploiting such synergy are also disclosed.... Agent: Mcdermott Will & Emery LLP Attn: Intellectual Property Deptartment

20070014720 - Antibodies directed to cd20 and uses thereof: Antibodies directed to the antigen CD20 and uses of such antibodies are disclosed herein. In particular, fully human monoclonal antibodies directed to the antigen CD20. Nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning... Agent: Knobbe Martens Olson & Bear LLP

20070014721 - Hydrazide conjugates as imaging agents: The present disclosure is directed to diagnostic agents. More specifically, the disclosure is directed to compounds, diagnostic agents, compositions, and kits for detecting and/or imaging and/or monitoring a pathological disorder associated with coronary plaque, carotid plaque, aortic plaque, plaque of the arterial vessel, aneurism, vasculitis, and other diseases of the... Agent: Louis J. Wille Bristol-myers Squibb Company

20070014718 - Kits for gastric emptying measurement: The present invention provides a test meal kits that are used in the diagnosis of gastrointestinal disorders characterized by changes in the rate of gastric emptying; and, with a breath test or a nuclear scintigraphy scan, are used to measure a half-gastric emptying time useful for therapy monitoring of gastrointestinal... Agent: Troxell Law Office PLLC

20070014722 - Method of treating human volume expansion mediated hypertension employing resibufogenin: A method of treating volume expansion mediated hypertension including administering a therapeutically effective dose of resibufogenin to a patient having volume expansion mediated hypertension. A method for the determination of the presence of volume expansion mediated hypertension may be by determining whether there has been a substantial elevation in marinobufogenin... Agent: Eckert Seamans Cherin & Mellott

20070014723 - Methods and compositions for 10beryllium complex probes: The present invention concerns methods and compositions for making and using Be complexes of defined compositions, which may have multiple functionalities and/or binding specificities. In various embodiment, Beryllium (Be) complexes may include Be such as 10Be and 7Be complexes. Such complexes find use in a wide variety of applications, particularly... Agent: Faegre & Benson LLP Patent Docketing

20070014719 - Steroid analogs and characterization and treatment methods: The invention relates to methods to characterize exemplified compounds such as 3β, 17β-dihydroxyandrost-1,5,11 -triene and 3β, 17β-dihydroxy-17α-ethynylandrost-1,5,11-triene and to the use of described compounds to ameliorate or treat a condition such as thrombocytopenia, inflammation or other exemplified conditions.... Agent: Hollis-eden Pharmaceuticals, Inc.

20070014725 - Conjugates of macrocyclic metal complexes with biomolecules and their use for the production of agents for nmr diagnosis and radiodiagnosis as well as radiotherapy: The invention relates to conjugates that consist of macrocyclic metal complexes with biomolecules and their production. The conjugates are suitable as contrast media in NMR diagnosis and radiodiagnosis as well as as agents for radiotherapy. High relaxivity is achieved by a special liganding of macrocyclic compounds, and a fine-tuning of... Agent: Millen, White, Zelano & Branigan, P.C.

20070014724 - Interferon alpha antibodies and their uses: The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules... Agent: Baker Botts, LLP

20070014726 - Oxidation-resistant indicator macromolecule: In one aspect, the present invention relates to an implantable device for detecting the presence or concentration of an analyte in an aqueous environment in vivo. The device includes a macromolecule that comprises a copolymer of: a) one or more indicator component monomers which individually are not sufficiently water soluble... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070014727 - Contrast media for nuclear spin tomography with use of the overhauser effect: The invention relates to contrast media for nuclear spin tomography (or else magnetic resonance tomography, MRT) with use of the Overhauser effect, which are suitable for transferring the magnetic orientation of electron spins to adjacent proton spins.... Agent: Millen, White, Zelano & Branigan, P.C.

20070014730 - Compositions containing magnetic iron oxide particles, and use of said compositions in imaging methods: The present invention relates to complexes which contain polycrystalline magnetic iron oxide particles in a pharmaceutically acceptable shell, and to the use of these compositions in magnetic particle imaging (MPI). Particular preference is given to the use of these compositions in examining the gastrointestinal tract, the vascular system of the... Agent: Millen, White, Zelano & Branigan, P.C.

20070014729 - Tissue engineered scaffolds and mehtods of preparation thereof: There is provided scaffolds for tissue repair/augmentation/implant comprising an acellular matrix, a biocompatible polymer and a biomimetic agent. The scaffolds advantageously supports cell growth in the target tissue. There is also provided a method for the preparation of the scaffold and for monitoring the functionality of the scaffold in tissue... Agent: Bereskin And Parr

20070014731 - Contrast agents: The present invention provides contrast agents for use in diagnostic ultrasound studies comprising microbubbles of gas or a gas precursor encapsulated by non-proteinaceous crosslinked or polymerised amphiphilic moieties.... Agent: Royal N. Ronning, Jr. Kenyon & Kenyon LLP

20070014728 - Device and method for increasing the throughput of irritation testing of transdermal formulations: A flexible test device and a method for irritation testing of formulations on skin. The test device includes a flexible substrate, a group of formulations secured on the flexible patch for application on the skin of an animal such that the test device conforms to the skin for the formulations... Agent: Philip S. Johnson Johnson & Johnson

20070014732 - Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent: Disclosed in certain embodiments is an oral dosage form comprising: a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and an irritant in an effective amount to impart an irritating sensation to an abuser upon administration of the dosage form after tampering.... Agent: Davidson, Davidson & Kappel, LLC

20070014735 - Buccal delivery system: A delivery formulation and system for delivering inactivated bioactive peptides to the body. The formulation includes effective amounts of the peptide as well as a mucosal permeation enhancer selected from the group consisting of quaternary ammonium salts. The system can be used by spraying the formulation into the buccal cavity,... Agent: Lott & Friedland, P.A.

20070014734 - Glucuronidated nebivolol metabolites: This invention provides glucuronidated nebivolol metabolites and pharmaceutical compositions of glucuronidated nebivolol metabolites for treatment of cardiovascular diseases. In addition, this invention also provides compositions comprising nebivolol and/or at least one glucuronidated metabolite of nebivolol and/or at least one other active compound in a pharmaceutically acceptable carrier. This invention also... Agent: Karlyn A. Schnapp Frost Brown Todd LLC

20070014733 - Hydroxylated nebivolol metabolites: Hydroxylated nebivolol metabolites increase NO release from human endothelial cell preparations in a concentration dependent fashion following acute administration. In addition, hydroxylated nebivolol metabolites, including but not limited to 4-hydroxy-6,6′difluoro-, 4-hydroxy-5-phenol-6,6′difluoro-, and 4-hydroxy-8-pheno-6,6′difluoro-, have the ability to increase the capacity for NO release in human endothelial cells following chronic administration.... Agent: Karlyn A. Schnapp Frost Brown Todd LLC

20070014736 - Methods of delivering corticotroph-derived glycoprotein hormone: Methods for treating diseases comprising delivering CGH by aerosol delivery and comprising administering a lesser amount of CGH than TSH are described.... Agent: Zymogenetics, Inc. Intellectual Property Department

20070014737 - Delivery of muscle relaxants through an inhalation route: The present invention relates to the delivery of muscle relaxants through an inhalation route. Specifically, it relates to aerosols containing muscle relaxants that are used in inhalation therapy. In a method aspect of the present invention, a muscle relaxant is delivered to a patient through an inhalation route. The method... Agent: Swanson & Bratschun, L.l.c

20070014738 - Particles for inhalation having sustained release properties: The invention generally relates to a method for pulmonary delivery of therapeutic, prophylactic and diagnostic agents to a patient wherein the agent is released in a sustained fashion, and to particles suitable for use in the method. In particular, the invention relates to a method for the pulmonary delivery of... Agent: Elmore Patent Law Group, PC

20070014739 - Compositions and methods for controlling biofilms and bacterial infections: The present invention provides compounds and compositions useful for controlling bacterial biofilms as well as for controlling and/or preventing bacterial infections. The compounds of the invention are pentacyclic acid triterpenes. Methods for controlling biofilms and for controlling and/or preventing bacterial infections are also disclosed.... Agent: Thompson Coburn, LLP

20070014740 - Oral compositions having cationic active ingredients: An oral composition is provided covering one or more cationic active ingredients and a cationic-compatible inorganic particulate having a porous surface that is substantially inert to the cationic active ingredient. The oral composition also has a cationic-compatible surfactant system and a carrier that is stable in the presence of the... Agent: Colgate-palmolive Company

20070014741 - Collagen eucalyptus toothpaste: A toothpaste, dental cream, or mouth spray composition for soothing the gums and teeth has base ingredients such as sorbitol, hydrated silica, polyethylene glycol and water; and a combination of eucalyptus oil and collagen, being present at less than about 10% by weight.... Agent: Law Offices Of Clement Cheng

20070014742 - Integrin binding motif containing peptides and methods of treating skeletal diseases: Peptide sequences comprising 10 to 50 amino acids are disclosed. The sequences are characterized by containing at least one of an integrin binding motif such as an RGD sequence, a glycosaminoglycan binding motif, and a calcium binding motif, and the remainder of amino acids contiguous with the RGD sequence in... Agent: Bozicevic, Field & Francis LLP

20070014743 - Subunguicide, and method for treating onychomycosis: Onychomycosis is a fungal infection of the nail bed and is difficult to treat topically because penetration of the nail plate is difficult, and systemic antifungal treatments are prone to side effects and drug interactions. The present invention treats onychomycosis by applying an antifungal composition to the nail bed directly... Agent: Bradley N. Ruben, PC

20070014744 - Preparation, in particular cosmetic preparation, process for the production thereof, and use thereof: A preparation, in particular a cosmetic preparation, in the form of an O/W emulsion, which besides usual cosmetic ingredients, contains a wax component, a fatty acid, a polyvalent alcohol, a film-forming agent and a gel component, wherein the gel component comprises a hydrocolloid.... Agent: Bachman & Lapointe, P.C.

20070014745 - Skin make-up composition comprising a resin: The present invention relates to a skin make-up or care composition containing a liquid fatty phase having at least one resin having a number-average molecular weight of less than or equal to 10 000 g/mol, chosen from rosin, rosin derivatives, hydrocarbon-based resins, and mixtures thereof. The invention also relates to... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070014746 - Hydrophobic emulsions containing polymers and process for obtaining same: wherein R1 represents a linear or branched alkyl, aryl or alkaryl radical having 8 to 22 carbon atoms, R2 represents hydrogen or (CH2CH2O)nR1 and n represents a number between 2 and 150, (d) 0 to 15% by weight of aralphatic compounds having at least one double bond in the aliphatic... Agent: Cognis Corporation Patent Department

20070014747 - Novel peptidic conjugates for alopecia preventive and curative treatment: The invention relates to novel peptidic conjugates containing a Gly-His-Lys sequence and used for dermatology or cosmetology for stimulating hair growth or stopping hair fall.... Agent: Birch Stewart Kolasch & Birch

20070014748 - Urea compounds that promote desquamation: e

20070014749 - Novel base material for pharmaceutical and/or cosmetic cream (herbal composition for itchy or infected skin): As well as for the promotion of non carrier state of the human beings and animals from some pathogenic bacteria such as staphylococci. The compositions are based on extracts from the plants Cassia tora, Centratherum anthelminticum and/or Melia azadirachta. A variety of other herbal extracts may be included and the... Agent: Dr Eladevi Shah

20070014750 - Composition to accelerate the exponential growth of lag phase-preserved heterotrophic bacteria: Broiler chickens are grown in barns with poultry litter, typically 4-6 inches of pine bark shavings. Growing chickens live on this litter, adding their manure to the litter bed. A liquid top dressing of alkaline-soluble, oxidized humic acid and non indigenous bacteria between flocks can release ammonia harmlessly to the... Agent: John R. Lively, Jr.

20070014751 - Novel spiro-quinuclidinyl derivatives for the treatment of central nervous system disorders: The present invention is directed to novel spiro-quinuclidinyl derivatives, pharmaceutical compositions containing them and their use in the treatment of central nervous system disorders.... Agent: Philip S. Johnson Johnson & Johnson

20070014752 - Surface functionalization of polymeric materials: The present invention relates to methods for functionalizing a surface, comprising exposing a surface of a polymeric material to an atmospheric pressure glow plasma discharge, wherein exposure to the plasma discharge functionalizes the surface of the polymeric material. The present invention further provides for methods for functionalizing a polymeric material,... Agent: Baker & Botts

20070014753 - Solvent-free, self-polishing polyurethane matrix for use in solvent-free antifoulings: A polyol having the formula X(O—R1—OH)m(O—R2)nHq. X is Si, C, B, Ti, P, Al, Mg, or Ca. Each R1 is derived from dipropylene glycol or tripropylene glycol, and each R2 is an aliphatic group. m is 2, 3, or 4; n is 0, 1, or 2; and q is 1... Agent: Naval Research Laboratory Associate Counsel (patents)

20070014756 - Composition and method for treating the gastro-intestinal tract: The invention provides a physiologically acceptable polymeric material having one or more ligands capable of binding to a receptor in a human or animal gut, said receptor being selected from the group consisting of carbohydrate, amino-acid, lipid and peptide receptors, characterised in that the polymeric material is substantially incapable of... Agent: Eric D. Cohen

20070014757 - Compositions and complexes containing a macromolecular compound as potential anti-inflammatory agents: A composition exhibiting anti-inflammatory activity comprising of a momodisperse macromolecular polymers such as dendrimer having a plurality of terminal groups or such molecules bound/complexed to drug moieties having anti-inflammatory activity or which assist in anti-inflammatory activity and its use in the pharmaceutical formulation for treating disease or pathological conditions associated... Agent: Foley And Lardner LLP Suite 500

20070014754 - Functionalized dendritic polymers for the capture and neutralization of biological and chemical agents: The present invention describes compositions and methods for sorbing and/or destroying dangerous substances such as chemical and biological warfare agents. The present invention relates to dendritic polymers, specifically, to quaternary ammonium functionalized dendritic polymers and N-Halamine functionalized dendritic polymers. Such dendrimers are useful for the capture and neutralization of biological... Agent: Pepper Hamilton LLP 50th Floor

20070014755 - Wound healing polymeric networks: A composition includes at least one biologically active agent covalently attached to a first polymerizing molecule that is adapted to undergo a free radical polymerization. The first polymerizing molecule retains the ability to undergo free radical polymerization after attachment of the bioactive agent thereto. The first polymerizing molecule is preferably... Agent: Bartony & Hare

20070014758 - Packaging materials for ophthalmic lenses: Packaging material for ophthalmic lenses, such as contact lenses, includes graphics with at least one of a right-side facial profile or a left-side facial profile. The graphics permit designating the lens included in the packaging for right or left eye placement.... Agent: Bausch & Lomb Incorporated

20070014760 - Enhanced recovery following ocular surgery: An ocular method comprising localized ocular administration of a pharmaceutically acceptable formulation and effective concentration of at least one neuro-stimulatory agent, which may include a macrolide, for a duration sufficient to at least partially restore corneal sensation, or at least one macrolide to reduce scarring after ocular surgery. The neuro-stimulatory... Agent: Wood, Herron & Evans, LLP

20070014759 - Glycopegylated granulocyte colony stimulating factor: The present invention provides conjugates between Granulocyte Colony Stimulating Factor and PEG moieties. The conjugates are linked via an intact glycosyl linking group that is interposed between and covalently attached to the peptide and the modifying group. The conjugates are formed from both glycosylated and unglycosylated peptides by the action... Agent: Morgan, Lewis & Bockius LLP (sf)

20070014761 - Heterodimeric four helix bundle cytokines: Heterodimeric proteins comprising two helical bundle cytokines are disclosed. One of the polypeptides comprises zsig81 and a second polypeptide which comprises either p19 (aka IL-12A) or p35 (aka L-12A). The proteins may be produced as fusion proteins or expressed as a single chain. The heterdimeric protein comprising zsig81 and p19... Agent: Zymogenetics, Inc. Intellectual Property Department

20070014762 - Pegylated g-csf polypeptides and methods of producing same: A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to... Agent: Maxygen, Inc. Intellectual Property Department

20070014763 - Pegylated g-csf polypeptides and methods of producing same: A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to... Agent: Maxygen, Inc. Intellectual Property Department

20070014765 - Methods for treating renal cell carcinoma: Methods for treating renal cell carcinoma using low doses of IL-2 are disclosed. In particular, the invention relates to methods of treating metastatic renal cell carcinoma in patients who are renally impaired and/or intolerant of high dose IL-2 therapy. The therapeutic regimen described herein significantly inhibits tumor growth with reduced... Agent: Novartis Vaccines And Diagnostics Inc.

20070014764 - Reduction in myocardial infarction size: This invention provides methods and compositions used for reducing the Myocaidial Infarct (MI) size in diabetic subjects exhibiting the haptoglobin (Hp) 2 allele. Specifically, the invention relates to reduction of MI in diabetic subjects carrying the Hp-2 allele by reducing the oxidative sterss in these subjects following ischemia-reperfusion injury.... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20070014769 - Adenovirus vectors comprising meganuclease-type endonucleases, and related systems: The present invention relates to methods for efficient and reliable construction of adenovirus vectors which contain and express foreign DNA and are useful for gene transfer into mammalian cells, for vaccines and for gene therapy. The invention provides for the growth and purification of adenovirus vectors (helper dependent vectors or... Agent: Beusse Wolter Sanks Mora & Maire, P. A.

20070014768 - Combined tumor suppressor gene therapy and chemotherapy in the treatment of neoplasms: In one embodiment, this invention provides methods of treating mammalian cancer or hyperproliferative cells, said method comprising contacting said cells with a tumor suppressor protein or tumor suppressor nucleic acid and also contacting said cell with at least one adjunctive anti-cancer agent. The invention also provides for a pharmacological composition... Agent: Townsend And Townsend And Crew, LLP

20070014766 - Compositions and methods for treating and preventing heart tissue degeneration, and uses thereof: The present invention provides methods for promoting generation of heart tissue, and for treating and preventing heurt tissue degeneration. Additionally, the present invention provides a therapeutic composition comprising a cyclin-associated agent, and a kit comprising the composition. The present invention further provides a heart tissue tell, a sidepopulation progenitor tell,... Agent: Thelen Reid & Priest LLP Leslie G. Restaino

20070014767 - Tgfbeta1-inhibitor peptides: Antagonistic synthetic peptides, obtained from TGFβ1 or from its receptors in the organism, that can be used in the manufacture, both on their own, as well as the gene sequences that encode them and the recombinant systems that express them, in the manufacture of compositions for use in the treatment... Agent: Ladas & Parry

20070014774 - Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α (1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl... Agent: Mckee, Voorhees & Sease, P.L.C

20070014775 - Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase: The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. Through ex vivo gene therapy protocols tumor cells are engineered to express an α(1,3) galactosyl epitope. The cells are then irradiated or otherwise killed and administered to a patient. The α galactosyl epitope... Agent: Mckee, Voorhees & Sease, P.L.C

20070014773 - Compositions for regenerating defective or absent myocardium: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition may also include an extracellular matrix scaffold component of any formulation, and further include added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. Methods... Agent: Leigh H. Firestone

20070014770 - Bacteriophage and their uses: There is provided a bacteriophage capable of lysing a P. acnes bacterium and incapable of lysing a bacterium which is not P. acnes, and which is incapable of sustaining lysogeny in a bacterium. There is also provided a pharmaceutical composition comprising such a bacteriophage.... Agent: Nixon & Vanderhye, PC

20070014772 - Engineered biografts for repair of damaged myocardium: A method for repairing a damaged myocardium in a mammal, comprising: a) providing a three-dimensional porous polysaccharide matrix; b) introducing mammalian cells into said matrix; c) growing said cells in said matrix in vitro, until a tissue-engineered biograft is formed, comprising a contracting tissue; and d) transplanting the tissue-engineered biograft... Agent: Merchant & Gould PC

20070014771 - Postpartum cells derived from umbilical cord tissue, and methods of making and using the same: Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described.... Agent: Woodcock Washburn LLP

20070014776 - Identification of adiponutrin-related proteins as esterases and methods of use for the same: The present invention provides methods of identifying polypeptides that have enzymatic activity associated with nutrient and/or energy homeostasis, and thus, are involved in the development of one or more cardiovascular and metabolic disorders, e.g., cardiovascular disease, obesity, insulin resistance, type 2 diabetes, dyslipidemia, nonalcoholic fatty liver disease, and metabolic syndrome.... Agent: Fitzpatrick Cella (wyeth)

20070014778 - Endoribonuclease and uses thereof: The invention provides in part a substantially pure endoribonuclease, having a molecular weight of about 34-48 KDa on a 12% denaturing sodium dodecyl sulfate polyacrylamide gel and capable of preferentially cleaving a RNA molecule at sites 3′ of uracil residues or sites 5′ of adenine residues. The invention provides methods... Agent: Ralph A. Dowell Of Dowell & Dowell P.C.

20070014777 - Protein compositions for promoting wound healing and skin regeneration: Methods for stimulating proliferation and inhibiting death of cells in the epidermis and dermis of wounded and non-wounded as well as transplanted mammalian skin and transplanted skin cell suspensions are described. The methods include the steps of administering to an area of wounded or non-wounded skin therapeutically effective amounts of... Agent: Faegre & Benson LLP Patent Docketing

20070014779 - Plasminogen activator variant formulations: A solution is provided comprising about 0.01-0.05 mg/mL of tenecteplase in sterile water for injection or bacteriostatic water for injection and normal saline. Such solution is useful for delivery from a catheter and for treating a thrombotic disorder by exposing fibrin-rich fluid from the disorder to an effective amount thereof,... Agent: Genentech, Inc.

20070014781 - Methods for using an elastase: The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have... Agent: Fried, Frank, Harris, Shriver & Jacobson LLP

20070014780 - Storage-stable human fibrinogen solutions: Methods are provided for the stable storage of ready-to-use, biocompatible human fibrinogen, which despite its concentration, remains available in fluid form, and which will permit long-term rapid and easy processing into a tissue adhesive preparation. Also provided is the sterile, storage-stable aqueous fibrinogen product resulting from the use of the... Agent: Christopher J. Woolverton

20070014782 - Systems for enlarging the diameter of an artery or vein: The invention provides methods for treating an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have... Agent: Fried, Frank, Harris, Shriver & Jacobson LLP

20070014783 - Use of collagenase to facilitate guide wire crossing in total arterial occlusions: The use of a collagenase containing formulation for degrading collagen within an occlusive atherosclerotic plaque in a chronic fibrotic occlusion, chronically occluded animal tube or cavity. A medical-related apparatus is provided comprising a medical-related device having provided thereto a therapeutic amount of a collagen degrading composition comprising a proteiolytic enzyme... Agent: Torys LLP

20070014784 - Methods and systems for treating injured cardiac tissue: Methods and systems are disclosed for treating injury to cardiac tissue by delivering a composition which provides structural support to the cardiac tissue. The composition helps to prevent chamber remodeling by providing structural reinforcement of the tissue or structural reinforcement of the tissue combined with biological therapy. The structurally reinforcing... Agent: Medtronic Vascular, Inc.IPLegal Department

20070014785 - Use of antibodies against cd20 for the treatment of the graft versus host disease: It is described the use of antibodies against exogenous surface antigens not present on normal human T lymphocytes for the preparation of compositions for the treatment of the graft versus host disease in patients who have received T lymphocytes transduced with such exogenous surface antigens.... Agent: Young & Thompson

20070014787 - 71 human secreted proteins: The present invention relates to novel human secreted proteins and isolated nucleic acids containing the coding regions of the genes encoding such proteins. Also provided are vectors, host cells, antibodies, and recombinant methods for producing human secreted proteins. The invention further relates to diagnostic and therapeutic methods useful for diagnosing... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070014789 - Humanized antibody conjugates and related methods, assays, reagents, and kits: The invention provides synthetically and recombinantly-derived humanized antibody conjugates and related methods, diagnostic assays, reagents, and kits. In one embodiment, the invention provides humanized antibody conjugates comprising a human immunoglobulin fragment which is bound by a cross-linking functional group to a non-human antibody fragment (e.g., a non-human monoclonal antibody fragment)... Agent: Bayer Healthcare, LLC Law & Patents Dept

20070014788 - Laminin-5 modulators and uses thereof: Described herein are methods of treating or preventing various diseases and disorders using modulators of laminin-5. Exemplary diseases and disorders are inflammatory bowel disease, including ulcerative colitis and Crohn's disease, as well as polycystic kidney disease and cancers associated with one or more of the aforementioned conditions. Exemplary laminin-5 modulators... Agent: Novo Nordisk, Inc. Patent Department

20070014786 - Methods for treating taxol-induced gut disorder: This invention relates to the field of taxol-induced gut disorder. More specifically, the invention relates to methods of treating taxol-induced gut disorder comprising administration of agonist anti-trkC antibody for the treatment, prevention, and/or amelioration of a symptom of taxol-induced gut disorder.... Agent: Morrison & Foerster LLP

20070014793 - Antibodies which activate an erythropoietin receptor: Antibodies and fragments thereof which activate an erythropoietin receptor and stimulate erythropoiesis are described. Also described are hybridoma cell lines which produce the antibodies and methods and compositions for the treatment of anemia.... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070014792 - Egfr inhibitors promote axon regeneration: Compositions and methods for promoting neural regeneration in a patient determined to have a lesion in a mature CNS neuron are disclosed. The method comprises the step of contacting the neuron with an EGFR inhibitor sufficient to promote regeneration of the neuron.... Agent: Richard Aron Osman Science And Technology Law Group

20070014794 - Method for making heteromultimeric polypeptides: The invention relates to a method of preparing heteromultimeric polypeptides such as bispecific antibodies, bispecific immunoadhesins and antibody-immunoadhesin chimeras. The invention also relates to the heteromultimers prepared using the method. Generally, the method involves introducing a protuberance at the interface of a first polypeptide and a corresponding cavity in the... Agent: Genentech, Inc.

20070014791 - Rage-related methods and copositions for treating glomerular injury: This invention provides methods, compositions and articles of manufacture for inhibiting the onset of and treating glomerular injury. The instant invention is based on the blockade of RAGE and/or RAGE G82S function.... Agent: Cooper & Dunham, LLP

20070014790 - Transcription control factor zhx3: To determine the biological role of ZHX1, found previously, which acts as a transcriptional repressor, the inventors conducted a search of ZHX1—interacting proteins using a yeast two-hybrid system. Molecular cloning and determination of the nucleotide sequence of the full-length cDNA encoding a novel protein revealed a novel protein with SEQ... Agent: Buchanan, Ingersoll & Rooney PC

20070014798 - Antibodies to dendritc cells and human dendritic cell populations and uses thereof: Described are novel antibodies specifically recognizing a distinct population of human dendritic cells (DCs) and methods of isolating said DCs using said antibodies. Furthermore, antigens and epitopes recognized by the above-described antibodies as well as polynucleotides encoding said antibodies are provided. Also provided are vectors comprising said polynucleotides as well... Agent: Foley And Lardner LLP Suite 500

20070014795 - Compositions and methods for enhanced dendritic cell maturation and function: This invention relates to compositions comprising an agent, which inhibits signaling via the FcγRIIB receptor and an agent which stimulates or enhances signaling via an FcγRI receptor, an FcγRIIa receptor, an FcγRIII receptor, or a combination thereof. The invention also provides for the use of such compositions in stimulating or... Agent: Pearl Cohen Zedek Latzer, LLP Suite 1001

20070014796 - Method for the production of non-immunogenic proteins: A target protein is rendered less immunogenic to a given species by (a) determining at least part of the amino acid sequence of the target protein; (b) identifying in the amino acid sequence one or more potential epitopes for T-cells (“T-cell epitopes”) of the given species; and (c) modifying the... Agent: Olson & Hierl, Ltd.

20070014797 - Method for treating sjogren's syndrome: A method of treating Sjögren's syndrome in a patient eligible for treatment is provided involving administering an effective amount of an antagonist that binds to a B-cell surface marker to the patient to provide significant improvement over baseline in two or more of dryness, fatigue, and joint pain on a... Agent: Genentech, Inc.

20070014799 - Antibody and use of the same: The present invention provides a novel antibody useful in developing therapeutic, preventive and diagnostic agents for diseases associated with human ZAQL-2, a method of quantifying ZAQL-2 by using the antibody, etc. More particularly, the present invention provides an antibody reacting specifically with human ZAQL-2 or its derivatives, a method of... Agent: Foley And Lardner LLP Suite 500

20070014800 - Cytokine zalpha11 ligand antibodies: Antibodies that bind to polypeptides and peptides comprising the sequence of zalpha11 Ligand as shown in SEQ ID NO: 2 are described. The antibodies may bind the full length sequence of 162 amino acid residues or a fragment thereof, including a mature polypeptide of 131 amino acid residues and smaller... Agent: Zymogenetics, Inc. Intellectual Property Department

20070014801 - Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer: Described herein are genes whose expression are up-regulated or down-regulated in prostate cancer. Also described are such genes whose expression is further up-regulated or down-regulated in drug-resistant prostate cancer cells. Related methods and compositions that can be used for diagnosis and treatment of prostate cancer are disclosed. Also described herein... Agent: Albert P. Halluin Howrey Simon Arnold & White, LLP

20070014802 - Modified antibody fragments: The present invention relates to a new class of antibody fragments including antibody Fab and Fab′ fragments in which the heavy chain is not covalently bonded to the light chain and two or more effector molecules are attached to the fragment, of which at least one of said molecules is... Agent: Woodcock Washburn LLP

20070014803 - Methods and compositions for diagnosis and treatment of viral and bacterial infections: The invention provides method and compositions for determining the presence and amount of a virus such as HIV-1, HIV-2, Hepatitis B, Hepatitis C, RSV, Rotavirus A, and M. tuberculosis in a sample. Also provided are methods for determining whether a subject is infected with HIV, as well as, the type.... Agent: Townsend And Townsend And Crew, LLP

20070014805 - Immuno-adjuvant emulsion: The invention relates to an oil-in-water adjuvant emulsion which comprises at least: squalene, an aqueous solvent, a polyoxyethylene alkyl ether nonionic surfactant, a hydrophobic nonionic surfactant, which emulsion is thermoreversible, and wherein 90% of the population by volume of the oil drops has a size less than 200 nm. The... Agent: Mcdonnell Boehnen Hulbert & Berghoff LLP

20070014804 - Peptidic nanoparticles as drug delivery and antigen display systems: Described is a new type of nanoparticle using the concept of self-organization of a single continuous chain to form peptidic nanoparticles. In particular, nanoparticles of the invention consist of aggregates of a continuous chain comprising two peptidic oligomerization domains connected by a linker segment. Preferred are coiled-coil oligomerization domains with... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070014806 - Universally applicable blood plasma: A universally applicable blood plasma obtainable by a process comprising the steps of mixing blood or blood plasma of blood groups A and B optionally blood or blood plasma of blood group AB without admixing substantial amounts of blood or blood plasma derived from blood group 0.... Agent: Jacobson Holman PLLC

20070014809 - B cell activation and polypeptides having cd14 activity: A novel protein purified from bovine colostral whey and isolated nucleotide sequences encoding the protein is identified. The isolated bovine protein is termed Bovine Lactation Associated Immunotropic (Bo-LAIT) protein. The human homologue of Bo-LAIT protein, Hu-LAIT protein, is also described. A method of activating B cells, and particularly of activating... Agent: Torys LLP

20070014807 - Multiplex vaccine: The present invention provides antigen complexes comprising 15 or more, in some instances 15 to 100 or more, different antigens and/or compositions comprising the antigen complexes where the composition comprises 15 or more, in some instances 15 to 100 or more, different antigens. The invention also provides to methods of... Agent: Morrison & Foerster LLP

20070014808 - Polypeptide: The present invention provides 5T4 tumour-associated antigen (TAA) for use in a method of immunotherapy of tumours. The invention also relates to a recombinant poxvirus vector from which at least one immune evasion gene has been deleted, which comprises a nucleic acid sequence encoding a 5T4 TAA and the use... Agent: Townsend And Townsend And Crew, LLP

20070014810 - Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions: This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines directed towards HPV. More specifically, this application communicates our discovery of pharmaceutical compositions and methods of use in the prevention and... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070014811 - Agents for treating osteoporosis and inhibiting osteoclast formation: The present invention provides a composition that effectively prevents the manifestation of osteoporosis, the formation of osteoclasts and the suppression of decreasing spongy bone density. The composition primarily contains Cordyceps Sinensis or its processed product.... Agent: Castellano Malm PLLC

20070014812 - Carrier proteins for vaccines: The present invention provides, among other things, improved carrier proteins for antigen-based vaccines, including polysaccharide-based vaccines. An aspect of the invention advantageously employs tetanus toxin Fragment C.... Agent: Morgan & Finnegan, L.L.P.

20070014813 - Conserved motif of hepatitis c virus e2/ns1 region: The hypervariable region (E2HV) of the putative hepatitis C virus (HCV) glycoprotein E2/NS1, between about amino acid 384 to about amino acid 414, is a rapidly evolving region of HCV, and is likely to be under positive immune selection. A newly discovered motif within this hypervariable region is immunogenic and... Agent: Novartis Vaccines And Diagnostics Inc.

20070014814 - Webbed hiv envelope immunogens, methods for production and use of same: HIV envelope immunogens that display multivalent epitopes are provided. The immunogens are aggregated, “webbed” HIV envelope immunogens in which native envelope structures are stabilized due to interactions with multimeric derivatives of M9 scorpion toxin.... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070014815 - Lawsonia vaccine and methods of use thereof: The present invention provides improved vaccination methods for increased protection against ileitis. The methods provide for the vaccination of young animals, preferably piglets, between 10 and 26 days of age, vaccination of pregnant sows during the second or third stages of gestation, and a combination of these methods. Vaccination of... Agent: Erickson & Kleypas, L.L.C.

20070014816 - Method for treating a trigeminal neuralgia by peripheral administration of a neurotoxin: Methods for treating a trigeminal neuralgia by peripheral administration to a patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin.... Agent: Allergan, Inc.

20070014817 - Method for treating a trigeminal neuralgia by peripheral administration of a neurotoxin: Methods for regulating the serine protease of Plasmodium. Recombinant DNA constructs which express the Plasmodium serine protease, especially those comprising a sub2 3′UTR and coding segment which express a SUB2 a serine protease. Recombinant Plasmodium containing such constructs and exhibiting increased virulence. Methods for detecting virulent Plasmodium strains by detecting... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070014818 - Liquid formulations with high concentration of human growth hormone (hgh) comprising 1,2-propylene glycol: The present invention relates to liquid formulations of human growth hormone (hGH, somatropin) which are storage stable, show reduced or no crystallization on storage and are suitable for administration to the human or animal body. More particularly, the invention relates to liquid formulations of human growth hormone which are stable... Agent: Novartis Corporate Intellectual Property

20070014821 - Method of cancer screening; method of cancer treatment; and method of diabetes treatment: A method of cancer screening comprising the steps of administering the Blood CA 27,29 testing procedure; if the result is positive administering a mammogram; if the result is positive administering a needle biopsy; if the result is positive administering a PET scan; if the result is positive administering a blood... Agent: Michael A. O'neil, P.C.

20070014819 - Method of emulsifying phytosterol by natural saponin,emulsion prepared thereby and water dispersible phytosterol powder product: Method of emulsifying phytosterol by natural saponin is disclosed including mixing an oil phase having phytosterol dissolved therein and an aqueous phase having a natural hydrophilic surfactant (saponin) therein to obtain an emulsion of phytosterol. A water dispersible phytosterol powder product can be formed by drying the emulsion, which is... Agent: Patenttm.us

20070014820 - Opioid formulations: The present invention provides high-concentration formulations of opioids such as fentanyl or fentanyl congeners. The formulation of the invention comprises fentanyl or a fentanyl congener in concentrations significantly in excess of conventional formulations, e.g., on the order about 2-fold to about 10,000-fold greater than conventional formulations, e.g., currently commercially available... Agent: Durect Corporation

20070014822 - Acetals, use thereof as fragrances and methods for production thereof: n=0 or 1, and there is a single bond or double bond at the location of a broken line between two C atoms, any double bond present in the chain linking the aliphatic ring to the acetal group having the E or Z configuration, with the proviso that the number... Agent: Roylance, Abrams, Berdo & Goodman, L.L.P.

20070014823 - Multi phase personal care composition comprising compositions having similar rheology profile in different phases: Multi-phase personal care compositions comprising: (a) at least one personal care composition phase; and (b) at least one another personal care composition phase; wherein the phase (a) and said the phase (b) are visually distinct phases that are packaged in physical contact, wherein the phase (a) and the phase (b)... Agent: The Procter & Gamble Company Intellectual Property Division

20070014824 - Mosquito control method: Mosquito larvae control is accomplished by providing an anti-microbial carrier member that is placed in the standing water that serves as breeding grounds, whereby the concentration of bacteria and other microbial organisms that serve as food for the larvae is severely reduced or eradicated. By eradicating the food supply, the... Agent: Rogers Towers, P.A.

20070014825 - Ant bait attractive to many species of ants and useful in their rapid control: An attractant bait composition and method for the control of many species of ants which includes a food base, attractants, sweeteners, carriers, dispersants, surfactants, fragrances, preservatives and one or more toxicants; wherein the method of application is of an ant bait composition having delayed ant toxic action comprising an ant... Agent: Harry A. Pacini

20070014826 - Roach bait attractive to many species of roach and useful in their rapid control: An attractant bait composition has been discovered for the control of many species of roaches. A similar group of baits were also found to be effective for the control of wasps, flies, termites, and mosquitoes. The composition includes a food base, attractants, sweeteners, carriers, dispersants, surfactants, fragrances, preservatives and a... Agent: Harry A. Pacini

20070014829 - Biocatalytic and biomimetic generation of nitric oxide in situ at substrate/blood interfaces: Biocompatible materials that have the ability to release nitric oxide (NO) in situ at the surface-blood interface when in contact with blood. The materials which may be polymers (e.g., polyurethane, poly(vinyl chloride), silicone rubbers), metals, such as stainless steel, carbon, and the like are provided with biocatalysts or biomimetic catalysts... Agent: Julia Church Dierker Dierker & Associates, P.C.

20070014828 - Cross-linked nitric oxide-releasing polyamine coated substrates, compositions comprising same and method of making same: The invention provides a method for preparing a nitric oxide-releasing medical device. The method includes contacting an amine-functionalized silane residue with a substrate, e.g., a metallic substrate, contacting the amine-functionalized silane residue with a cross-linking agent, contacting at least one nucleophilic residue with the cross-linked amine-functionalized silane residue, and contacting... Agent: Leydig, Voit & Mayer, Ltd.

20070014827 - Gamma-tocopherol therapy for restenosis prevention: A stent is provided in combination with delivery of a tocopherol agent, and in particular a des-methyl tocopherol agent, and further beneficially a gamma-tocopherol agent, so as to reduce restenosis along the vessel or other lumenal wall where the stent is implanted. In particular applications, the stent is an endolumenal... Agent: Preston Gates & Ellis LLP Attn: C. Rachal Winger

20070014831 - Biodegradable occlusive device with moisture memory: The present invention relates to a biodegradable occlusive device and methods for treating aneurysm of a patient comprising deploying a flexible biodegradable occlusive device with a moisture memory and a controlled biodegradation, and deploying a retaining stent for preventing the occlusive device from being inadvertently dislodged from the sac.... Agent: Hosheng Tu

20070014830 - Drug-releasing sinus stent: The present invention relates to a stent, adapted for deployment in a nasal sinus, comprising a matrix metalloproteinase-inhibiting substance and capable of locally releasing in a controlled manner a therapeutically effective amount of said matrix metalloproteinase-inhibiting substance. The invention further relates to a method for treatment of a diseased or... Agent: Dicke, Billig & Czaja, P.l.l.c.

20070014832 - Therapeutic compositions and methods: Methods of promoting healing through enhanced regeneration of tissue (e.g. hard tissue or soft tissue) by contacting the tissue or the surrounding tissue with an anti-inflammatory agent. These methods are useful in a variety of dental and orthopedic applications.... Agent: Viksnins Harris & Padys Pllp

20070014833 - Treatment of eye disorders with sirtuin modulators: Sirtuin modulators, particularly sirtuin activators, are useful in treating vision impairment. In general, the sirtuin modulators inhibit the progression of vision impairment resulting from various eye disorders. The invention also includes pharmaceutically acceptable formulations of sirtuin modulators, particular ophthalmically acceptable formulations.... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070014834 - Apparatus and methods of improved delivery of orally-administered therapeutic substances: The present invention pertains to flavor- and/or therapeutically-enhanced delivery of orally-administered medicines, natural substances, therapeutic materials and the like; in particular, the invention relates to apparatus and methods for rendering such items more attractive to a subject in need of same. In some embodiments a theobromine material and/or some marshmallow... Agent: Paul H. Mcdowall

20070014835 - Blood purifier: A blood purifier includes a first material selected from a group made of copper material, platinum material and molybdenum material, a second material selected from a group made of black silica material, radon material, germanium material, neodymium material and silica material and a titanium oxide material. The blood purifier at... Agent: Greenblum & Bernstein, P.L.C

20070014838 - Catalytic enzyme-modified textiles for active protection from toxins: Catalytic enzyme-modified textiles are disclosed for providing protection from chemical exposure. The textiles are composed of a cloth substrate, at least one polyelectrolyte layer, at least one enzyme layer to degrade the chemical agent, and at least one capping layer. Also disclosed is the related method for making catalytic enzyme-modified... Agent: Naval Research Laboratory Associate Counsel (patents)

20070014836 - Cologne wipes: Cologne Wipes containers will be constructed of a corrugated cardboard type of material (for FIG. 1 of the drawings, a thin plastic type of material (for FIG. 2 of the drawings), and a thicker type of plastic for FIG. 3 of the drawings). The wipes themselves will be made of... Agent: Kelvin D. Hilton

20070014837 - System and method for use of agent in combination with subatmospheric pressure tissue treatment: A method and apparatus for the introduction to a wound under subatmospheric pressure therapy of a wound healing agent, generally comprises a foam pad (11) for insertion substantially into a wound site (12), and a wound drape (13) for sealing enclosure of the foam pad at the wound site. The... Agent: Legal Department Intellectual Property Kinetic Concepts, Inc.

20070014839 - Decomposer film for transdermal patches: The decomposer film product has a polymeric decomposer layer, a cover layer for protecting the decomposer film from the surroundings and a releasable support liner, which is removed prior to use. The polymeric decomposer film contains a water-soluble or water-insoluble polymeric adhesive material and a decomposition accelerator, which acts to... Agent: Striker, Striker & Stenby

20070014840 - Circular dumbbell decoy oligodeoxynucleotides (cdodn) containing dna bindings sites of transcription: The present invention provides a circular dumbbell oligodeoxynucleotide (CDODN) comprising two loop structures and a stem structure, wherein the stem structure comprises a nucleotide sequence capable of binding the DNA-binding domain of a transcriptional factor. The present invention further provides a pharmaceutical composition comprising said CDODN. The pharmaceutical composition can... Agent: Fish & NeaveIPGroup Ropes & Gray LLP

20070014845 - Liposomal delivery vehicle for hydrophobic drugs: A liposome composition having a high drug concentration of a hydrophobic drug and capable of retaining the drug in entrapped form is described. The liposomes are comprised of high phase transition lipid and a lipopolymer, which together permit retention of a high concentration of a drug/cyclodextrin complex that achieves a... Agent: Perkins Coie LLP

20070014844 - Method of treating patients with a mucinous glycoprotein (muc-1) vaccine: The present invention provides a method for treating an individual who is afflicted with a cancer, such as non-small cell lung cancer or prostate cancer, by administering to that individual a MUC-1-based formulation. The formulation may be a MUC-1 based liposomal vaccine formulation.... Agent: Foley And Lardner LLP Suite 500

20070014841 - Pharmaceutical compositions: The present invention relates to polypeptides, epitopes and antibodies directed to these epitopes, more particularly to the Sip polypeptide of Group B Streptococcus (GBS), also called Streptococcus agalactiae which may be used to prevent, diagnose and/or treat streptococcal infection.... Agent: Millen, White, Zelano & Branigan, PC

20070014842 - Pharmaceutical liposomal compositions: Pharmaceutical compositions comprising a liposome associated to N. meningitidis polypeptides fragments or analogs thereof or corresponding DNA fragments, can be used to prevent, diagnose and/or treat neisserial infections.... Agent: Millen, White, Zelano & Branigan, PC

20070014843 - Sustained release enhanced lipolytic formulation for regional adipose tissue treatment: Compositions, formulations, methods, and systems for treating regional fat deposits comprise contacting a targeted fat deposit with a composition comprising long acting beta-2 adrenergic receptor agonist and a compound that reduces desensitization of the target tissue to the long acting beta-2 adrenergic receptor agonist, for example, glucocorticosteroids and/or ketotifen. Embodiments... Agent: James W. Hill, M.d. Mcdermott Will & Emery

20070014847 - Coated capsules and methods of making and using the same: The present invention relates to coated capsules with increased capsule shell pliability and resilience and methods of making the coated capsules. The present invention relates to methods of making coated capsules, the methods comprising applying a coating solution comprising sodium carboxymethylcellulose or sodium alginate to the exterior of a capsule... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070014846 - Pharmaceutical compositions comprising fenofibrate and atorvastatin: Pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCatorvastatin) of between about 250 and about 10,000. The solid compositions are... Agent: Cheryl H Agris Phd

20070014848 - Resorbable polyetheresters and medicinal implants made therefrom: The invention relates to the use of absorbable block copolymers with polyether and polyester units for preparing surgical implants which are suitable for the human or animal body, and the block copolymers in question. The block copolymers used according to the invention and those which are new according to the... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070014849 - Use of ramoplanin to treat diseases associated with the use of antibiotics: The invention features a method of treating or preventing a disease associated with the use of antibiotics in a patient in need thereof by administering to the patient ramoplanin in an amount and for a duration effective to treat said disease. The disease may be caused, for example, by the... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070014854 - Novel granulation process: One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable... Agent: Kenyon & Kenyon LLP

20070014853 - Pharmaceutical dosage form containing novel pharmaceutical granulate: One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable... Agent: Kenyon & Kenyon LLP

20070014857 - Pharmaceutical formulation having a masked taste and method for the production thereof: The invention relates to a pharmaceutical formulation in the form of a powder which is administered orally in an aqueous suspension, having a masked taste, and comprising at least one cellulose polymer, a methacrylic polymer and an active ingredient which is distributed in a homogeneous manner in a molecular state... Agent: Ross J. Oehler Sanofi-aventis U.s. LLC

20070014850 - Process for the preparation of dispersible tablets of cephalexin: The present invention relates to dispersible tablets of cephalexin and a process for their preparation.... Agent: Jayadeep R. Deshmukh Ranbaxy Inc.

20070014856 - Rapidly disintegrable pharmaceutical composition: The present invention relates to a pharmaceutical composition useful for rapid disintegration, which comprises a sparingly soluble medicament held on a gel-forming water-soluble polymer as a solid dispersion, wherein it contains a salt substance that comprises an alkali and a weak or strong acid and has an endothermic standard enthalpy... Agent: Sughrue Mion, PLLC

20070014851 - Solid pharmaceutical preparation containing levothyroxine and/or liothyronine salts: In a solid pharmaceutical preparation containing water-soluble salts of levothyroxine and/or liothyronine as active ingredients, the water activity of said pharmaceutical preparation is adjusted to values of below 0.4 and, preferably, 0.1 to 0.3, measured at room temperature.... Agent: Robert J Schneider Chapman And Cutler

20070014855 - Stable desloratadine compositions: Stable pharmaceutical compositions of desloratadine or pharmaceutically acceptable salts in combination with one or more therapeutically active compounds.... Agent: Dr. Reddy's Laboratories, Inc.

20070014852 - Tablets having a printed separation mark to guide breaking: The invention provides a novel “separation marking” on a tablet as a means for assisting in the identification of a region on the tablet that is desired to be able to be broken from time to time. Said breaking allows production of smaller dosage forms known herein as tablettes. In... Agent: Hedman & Costigan P.C.

20070014858 - Method for controlling lag time of in-situ passageway formation in osmotic delivery system: An osmotically controlled delivery system includes a solid core having a shallow indentation on a surface of the core, and a semipermeable membrane enclosing the solid core. The solid core is made by a drug composition being caopable of generating an osmotically effective pressure, and the semipermeable membrane is relatively... Agent: Fish & Richardson PC

20070014859 - Highly bioavailable oral delayed release dosage forms of o-desmethylvenlafaxine succinate: An oral, highly bioavailable unit dosage form of O-desmethylvenlafaxine succinate (DVS) having a delayed release of at least about one hour and a sustained release over multiple hours to provide a total release of greater than about 85% within about 12 to about 14 hours is described. In one embodiment,... Agent: Howson And Howson Cathy A. Kodroff

20070014860 - Treatment of esophagitis: A method for treatment of esophagitis is disclosed in which a therapeutic composition is introduced into the esophagus to contact a mucosal surface within the esophagus. The pharmaceutical composition comprises a reverse-thermal gelation polyoxyalkylene block copolymer, a pharmaceutical substance and a pharmaceutical substance selected from the group consisting of glutathione... Agent: Marsh, Fischmann & Breyfogle LLP

20070014861 - Treatment of proctitis: A method for treatment of proctitis is disclosed in which a therapeutic composition is introduced into the rectum to contact a mucosal surface within the rectum. The pharmaceutical composition comprises a reverse-thermal gelation polyoxyalkylene block copolymer, a pharmaceutical substance and a pharmaceutical substance selected from the group consisting of glutathione... Agent: Marsh, Fischmann & Breyfogle LLP

20070014862 - Device for treating wound gaps: A hemostatic agent comprises oxidized cellulose in the form of a compressible, shapeable mass that can remain substantially in the compressed or shaped form for placement on a bleed site or into a wound gap. The oxidized cellulose may be a pellet of unwoven oxidized cellulose fibrous strands, or it... Agent: Michaud-duffy Group LLP

20070014865 - Chemically stable, dry-flow, low compact, dust free, soluble granules of phosphoroamidothioate prepared by a process of dry granulation by agitative balling: Chemically stable, dry-flow, low compact, dust free, soluble granules of phosphoroamidothioate are prepared using a substantially dry granulation process including an agitative balling process. In a preferred embodiment, spherically shaped acephate granules are produces without the intentional addition of water and/or solvents.... Agent: Jones, Tullar & Cooper, P.C.

20070014863 - Method of controlling paticle size of retinoic acid nanoparticles coated with polyvalent metal inorganic salt and nanoparticles obtained by the controlling method: Nanoparticles containing retinoic acid have reduced irritancy of retinoic acid and are suitable for subcutaneous or intravenous administration, as well as for use in sustained-release preparation. The high skin permeability of the nanoparticles makes them suitable for use in pharmaceutical or non-pharmaceutical external preparations or cosmetics intended for skin application.... Agent: Ostrager Chong Flaherty & Broitman PC

20070014864 - Novel pharmaceutical granulate: One of the objects of the invention relates to a pharmaceutical composition in the form of a granulate, wherein the granulates comprises an active pharmaceutical ingredient (API) having a poor water solubility intimately associated with at least one pharmaceutically acceptable sugar, and optionally or preferably at least one pharmaceutically acceptable... Agent: Kenyon & Kenyon LLP

20070014866 - Composition for improving the efficacy and reducing the side effects of omega 3 fatty acids, fish oils and cardiovascular and diabetic treatments: Synergistic therapeutic compositions for reducing triglycerides, lowering LDL and increasing HDL are formed by combining either pantethine or CoA, or a combination of pantethine and CoA with fish oils. Either pantethine or CoA, or a combination of pantethine and CoA, added to cardiovascular drugs or compositions for lowering cholesterol increases... Agent: Koppel, Patrick & Heybl

20070014867 - Acellular matrix implants for treatment of articular cartilage, bone or osteochondral defects and injuries and a method for use thereof: An acellular matrix implant for treatment of defects and injuries of articular cartilage, bone or osteochondral bone and a method for treatment of injured, damaged, diseased or aged articular cartilage or bone, using the acellular matrix implant implanted into a joint cartilage lesion in situ and a bone-inducing composition implanted... Agent: Peters Verny Jones & Schmitt, L.L.P.

20070014869 - Compositions for reconstruction, replacement or repair of intracardiac tissue: The invention is to a composition for reconstruction, replacement or repair of a defect in or dsmage to intracardiac tissue comprising a patch, emulsion, injectable solution or other composition comprising extracellular matrix. As extracellular matrix can assimilate with the intracardiac tissue to help generate healthy functioning tissue, using extracellular matrix... Agent: Leigh Hunt Firestone

20070014870 - Compositions for regenerating defective or absent myocardium: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition can also have an extracellular matrix scaffold component of any formulation, then including also added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. Methods... Agent: Leigh Hunt Firestone

20070014871 - Compositions for regenerating defective or absent myocardium: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition can also have an extracellular matrix scaffold component of any formulation, then including also added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. Methods... Agent: Leigh Hunt Firestone

20070014872 - Compositions for regenerating defective or absent myocardium: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition can also have an extracellular matrix scaffold component of any formulation, then including also added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. Methods... Agent: Leigh Hunt Firestone

20070014873 - Compositions for regenerating defective or absent myocardium: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition can also have an extracellular matrix scaffold component of any formulation, then including also added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. Methods... Agent: Leigh Hunt Firestone

20070014874 - Compositions for regenerating defective or absent myocardium: Compositions of the invention for regenerating defective or absent myocardium comprise an emulsified or injectable extracellular matrix composition. The composition can also have an extracellular matrix scaffold component of any formulation, then including also added cells, proteins, or other components to optimize the regenerative process and restore cardiac function. Methods... Agent: Leigh Hunt Firestone

20070014868 - Patch for reconstruction, replacement or repair of the pericardial sac: The invention is a patch for partial closure of the pericardial sac after open heart surgery. The patch comprises extracellular matrix material and is loosely tacked at the opening of the pericardium. The invention provides the opportunity for subsequent open heart surgeries without the risks involved in negotiating around the... Agent: Leigh Hunt Firestone

20070014875 - Novel drug delivery system for proton pump inhibitors and process thereof: The present invention discloses a novel drug delivery system for proton pump inhibitors comprising benzimidazole compounds or their salts, preferably Rabeprazole or its salts and pharmaceutically acceptable excipients in powder form which is reconstitutable in a parenterally acceptable solvent to form an injectable solution.... Agent: Blank Rome LLP

20070014876 - Synergistic compositions and method for potentiating anti-oxidative activity: The present invention relates to synergistic compositions for protection against oxidative damage, consisting essentially of antacids in conjunction with antioxidants. The invention further relates to method for preventing oxidative damage using the compositions of the invention.... Agent: Heslin Rothenberg Farley & Mesiti PC

20070014878 - Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition: Compositions and methods for administering the same to humans are provided for the promotion of increasing a person's natural metabolic rate, increasing thermogenesis, increasing training intensity, increasing muscular definition, and/or decreasing water retention. Said compositions may comprise, green tea extract, anhydrous caffeine, theobroma cocao extract, oolong tea extract, white tea... Agent: Kenyon & Kenyon LLP

20070014877 - Use of extracts from pelargonium species: The present invention relates to the use of extracts from Pelargonium species or plant parts thereof, particularly from P. sidoides and P. reniforme for the prophylaxis or treatment of disease-related behavioural changes, the chronic or post-viral asthenia syndrome and/or stress-induced chronic pathological conditions as well as pharmaceutical preparations containing these... Agent: Edwards & Angell, LLP

20070014879 - Composition comprising notoginseng radix extract for preventing and treating of arthritis as an effective ingredient: e

20070014880 - Method for preparing ginkgo extracts having a reduced content of nonpolar plant ingredients and nonpolar impurities due to enviromental influences: The invention further relates to an extract (liquid extract or spissum extract as well as dry extract) from ginkgo biloba having a reduced content of nonpolar plant ingredients and nonpolar impurities due to environmental influences compared to the initial extract, which is obtainable by the method of the present invention.... Agent: Edwards & Angell, LLP

20070014881 - Cosmetic formulations and skin treatment: A process of skin treatment to soften the skin and minimize wrinkles utilizes in the first step the spray application of a mist to the skin. This first step is followed by the application of a mixture of beneficial vegetable oils that with essential oils. The first step of the... Agent: Edward S. Sherman, Esq.

20070014882 - Ellagic acid and anti-coagulant compound: A compound comprising blood-thinning and or anti-coagulant ingredients mixed with ellagic acid and/or ellagitannin, said compound-taken orally.... Agent: Spencer Feldman

20070014883 - Method for treating osteoarthritis: The invention relates to methods for treating osteoarthritis by administering a composition consisting essentially of proanthocyanidins to a patient suffering from such a disorder.... Agent: Eric Sinn, Esq. Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.c

20070009432 - Boat tropanes: Radiopharmaceutical compounds are disclosed. A tropane compound is linked through the N atom at the 8-position to a chelating ligand capable of complexing technetium or rhenium to produce a neutral labeled complex that selectively binds to the dopamine transporter over the serotonin transporter with a ratio of 10 or more.... Agent: Edwards & Angell, LLP

20070009427 - Compounds and methods for enhanced delivery to disease targets: A set of compounds that includes an active-agent labeled species and a pretargeting conjugate is disclosed. The active agent-labeled species includes a ligand coupled to an active agent. The pretargeting conjugate includes a protein conjugated to a targeting species having a targeting moiety capable of binding to an in-vivo target... Agent: General Electric Company Global Research

20070009428 - Compounds and methods for enhanced delivery to disease targets: A set of compounds that includes an active-agent labeled species and a pretargeting conjugate is disclosed. The active agent-labeled species includes a ligand coupled to an active agent. The pretargeting conjugate includes a protein conjugated to a targeting species having a targeting moiety capable of binding to an in-vivo target... Agent: General Electric Company Global Research

20070009430 - Process for the production of a radioactive aerosol: A method for forming an inhalable isotope compound suitable for use in patient medical diagnosis, the method comprising the steps of: (a) electrolytic loading of a carbon crucible with the isotope; (b) sublimating any isotope carrier in the crucible; (c) ablating the isotope in a carbon crucible, forming an ablation... Agent: Pearne & Gordon LLP

20070009429 - Radiation resistant silicone formulations and medical devices formed of same: The disclosure is directed to a polymeric material formed of a composition including polyalkylsiloxane and a radiation resistant component. The radiation resistant component is included in an amount of about 0.1 wt % to about 20 wt % based on the weight of the polyalkylsiloxane.... Agent: Larson Newman Abel Polansky & White, LLP

20070009431 - Solution and method for supporting imaging on a patient: To support imaging on a patient, two different image recording methods are to be executed simultaneously. With each image recording method, a supporting fluid, for instance a contrast means or a tracer, can be introduced into the body of the patient. The invention proposes mixing the two supporting fluids with... Agent: Siemens Corporation Intellectual Property Department

20070009433 - 14094, a novel human trypsin family member and uses thereof: The invention provides isolated nucleic acids molecules, designated 14094 nucleic acid molecules, which encode a novel trypsin family member. Elevated expression of 14094 mRNA was detected in breast, ovarian, lung, and liver cancers compared to normal cells derived from these tissues. The invention also provides antisense nucleic acid molecules, recombinant... Agent: Millennium Pharmaceuticals, Inc.

20070009434 - Imaging and therapeutic method using monocytes: wherein the group Ab comprises a ligand that binds to monocytes, and when the conjugate is being used for treatment of the disease state, the group X comprises an immunogen, a cytotoxin, or a compound capable of altering monocyte function, and when the conjugate is being used for diagnosing the... Agent: Barnes & Thornburg LLP

20070009435 - Compositions and methods for enhanced delivery to target sites: A set of compounds that includes an active agent-labeled species and a pretargeting conjugate is disclosed. The active agent-labeled species includes a first oligomeric nucleotide or mimic thereof conjugated to a linker having a first moiety coupled with a diagnostic active agent. The pretargeting conjugate includes a second oligomeric nucleotide... Agent: General Electric Company Global Research

20070009437 - Intracellular trapping of radionuclides by enzyme-mediated reduction: Enzyme-mediated intracellular trapping of a radionuclide in a target cell is achieved by transfecting the target cell with a transgenic vector encoding a microbial hydrogenase expressible in the target cell and exposing the transfected target cell with a radionuclide. The transgenically expressed microbial hydrogenase catalyzes the reduction of the radionuclide.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070009436 - Radionuclide nanoparticles encased by inorganic shell having vector biomolecules attached thereto: A nanoparticle radionuclide delivery system includes a radionuclide core, a non-radioactive inorganic layer encasing the radionuclide core to form an encased radionuclide, at least one coupling moiety, and at least one vector biomolecule specific to a target tissue. The coupling moiety includes a first reactive group bound to the non-radioactive... Agent: Akerman Senterfitt

20070009438 - Method for diagnosing diabetes type 2 using standardized mixed meal and calculated index values: The present invention provides methods and materials for diagnosing a metabolic disorder comprising measuring insulin and HISS action or alternatively HISS levels, first in a fasting state and again, following consumption of a mixed standard meal. The metabolic disorders diagnosed using the disclosed methods and materials include insulin resistance, pre-diabetes... Agent: Merchant & Gould PC

20070009439 - Diabetogenic rat model: The present invention provides a method of producing diabetic rats, and a method for identifying compounds that reverse diabetes in said rats.... Agent: Hoffmann-la Roche Inc. Patent Law Department

20070009441 - Biodegradable nanoparticles: The present invention relates to polymeric nanoparticles useful in drug and agent delivery, as well as for imaging, diagnosis and targeting. The polymeric nanoparticles of the present invention comprise polymers and cross-linkers that, when degraded, leave simple nontoxic biocompatible molecules that can be metabolized, excreted, or absorbed by the body.... Agent: Sterne, Kessler, Goldstein & Fox PLLC

20070009442 - Macrocyclic metal complexes and their use for the production of conjugates with biomolecules: The invention relates to macrocyclic metal complexes and their production and use for the production of conjugates with biomolecules. The conjugates are suitable as contrast media in NMR diagnosis and radiodiagnosis as well as for radiotherapy. High relaxivity is achieved by a special liganding of macrocyclic compounds, and a fine-tuning... Agent: Millen, White, Zelano & Branigan, P.C.

20070009440 - Peptide conjugates and fluorescence detection methods for intarcellular caspase assay: Polypeptides labelled with a donor and acceptor pair of dyes selected from a dibenzorhodamine dye and a diamino-benzophenoxazine dye are peptide conjugates which are useful for intracellular and bead-based assays with fluorescence detection. Peptide conjugates with a caspase-recognition site undergo cleavage into peptide fragments which may be detected, located, and... Agent: Brinks Hofer Gilson & Lione

20070009443 - Method for inhibiting occupation by rhinovirus of cell in the nasal membrane: A composition and method for modifying the composition of a cell in a nasal epithelial membrane to improve the ability of the cell to defend against rhinovirus.... Agent: Tod R Nissle

20070009445 - Aerosol compositions and methods: The present invention provides drug formulations and methods that comprise omega-3 and/or omega-6 fatty acids, and their ester derivatives (e.g., methyl, ethyl, isopropyl, etc.), which are soluble in non-CFC propellants. The addition of omega-3 or omega-6 fatty acids to the aerosol formulations also provides therapeutic benefits.... Agent: Sullivan & Worcester LLP

20070009444 - Method for preparing powder exhibiting low susceptibility to electrification: A method of producing lowly-charged powder comprising drying a liquid composition containing a highly-charged compound and polyethyleneglycol.... Agent: Wenderoth, Lind & Ponack, L.L.P.

20070009446 - Low viscosity, unstable water-in-silicone emulsion cosmetic compositions and methods of use thereof: A low viscosity, unstable water-in-silicone emulsion cosmetic composition stabilized upon agitation comprising a volatile solvent, a water phase dispersed within the composition, at least one silicone film-forming polymer and at least one emulsifier, and methods of use thereof as a sprayable composition.... Agent: The Estee Lauder Cos, Inc

20070009449 - Dental gel etchants: Etching compositions, curable compositions, packaged products and methods of use for the treatment of bone substrate, i.e., teeth, are described. The etch compositions generally include a gelling agent, an inorganic acid, an organic acid and either a solvent, a surfactant or mixtures thereof. The curable composites include reactive monomers and... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070009448 - Silanol based dental treatment: Etching compositions, curable compositions, packaged products and methods of use for the treatment of bone substrate, i.e., teeth, are described. The etch solutions generally include an aqueous acidic solution with an ethylenically unsaturated monomer and a silane. The methods of the invention provide the ability to modify a bone or... Agent: Dorsey & Whitney LLP Intellectual Property Department

20070009447 - Toothpaste compositions with reduced abrasivity: Toothpaste compositions are disclosed. The toothpaste composition comprises a binder; a surface active agent; an abrasive; a humectant; and water, in which: (1) the abrasive is silica, the composition additionally comprises a silica thickener, and the composition comprises 1 to 7 wt % of the silica thickener, less than 15... Agent: Paul A Fair Fmc Corporation

20070009451 - Cosmetic and/or pharmaceutical compositions for the cure and prevention of irritation, inflammation and cutaneous erythema: The present invention has as subject a new composition for cosmetic or pharmaceutical use intended for external use to be applied both to undamaged and damaged skin or onto the mucosa to reduce or inhibit irritation, inflammation and cutaneous erythemia induced by events of an exogenous nature (irritations induced by... Agent: Shoemaker And Mattare, Ltd

20070009452 - Cosmetic bronzing agent based on dihydroxyacetone: A novel cosmetic bronzing agent based on dihydroxyacetone. the bronzing agent contains 0.1-4.5 wt. % dihydroxyacetone (DHA) mounted in a lamellar structure, 0.15-3.5 wt. % free dihydroxyacetone, whereby the ratio between mounted lamellar DHA and free DHA is located in the region of 1:1.5-1:0.25 and the total amount of DHA... Agent: Akerman Senterfitt

20070009453 - Photoprotective compositions comprising an aqueous phase and a low melting point apolar wax: Photoprotective cosmetic compositions having at least reduced shine, stickiness, whitening and/or fluffiness and/or enhanced SPF contain an effective amount of at least one UV radiation filtering agent, at least one aqueous phase and at least one apolar wax having a melting point greater than or equal to 30° C. and... Agent: Buchanan, Ingersoll & Rooney PC

20070009450 - Preparation, in particular cosmetic preparation, process for the...: A preparation, in particular a cosmetic preparation, in the form of a workable paste which is present in the form of an emulsion and which is suitable for cosmetic uses, in particular in the area of decorative cosmetics for colouring and improving the skin, the lips and the eyelids. The... Agent: Bachman & Lapointe, P.C.

20070009454 - Make-up method involving a magnetic interaction: A method of making up or decorating keratinous materials includes applying, to the keratinous materials, a first layer of a first composition or a first structure having magnetic properties. The method includes applying, to at least a portion of the first layer or first structure, a second layer of a... Agent: Oliff & Berridge, PLC

20070009455 - Whitening and antionxidative cosmetic composition containing resveratrol and method for preparing the same: Provided are a stabilized, skin-whitening and antioxidative cosmetic composition including resveratrol as a main component and either a primary stabilizer selected from cyclodextrin, polyethyleneglycol, and a mixture thereof, or a combination of the primary stabilizer and a secondary stabilizer selected from an alpha-lipoic acid, a water-soluble whitening composition, a phellodendron... Agent: Fish & Richardson PC

20070009456 - Pigmented anhydrous cosmetic compostition: The disclosure relates to an anhydrous cosmetic makeup composition comprising at least one volatile oil, at least one pigment in an amount greater than or equal to 25% by weight of pigments, and at least one oil-thickening agent, the composition having a hardness ranging from 0.04 to 0.5 newtons. The... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070009457 - Lipophilic personal care composition: wherein one of X and Y is an ester residue of sterol selected from the group consisting of phytosterol, cholesterol, lanosterol, stigmasterol, its hydrogenates, and its derivatives, and the other is selected from H, an alkyl or alkenyl of 8-30 carbons, and ester residue of monohydric solid alcohol of 12-38... Agent: The Procter & Gamble Company Intellectual Property Division

20070009458 - Lipophilic personal care composition: wherein one of X and Y is an ester residue of sterol, and the other is selected from H, a liquid alkyl or alkenyl of 8-30 carbons, and ester residue of monohydric solid alcohol of 12-38 carbons; COR is a long chain acyl group of 8-22 carbons; and n is... Agent: The Procter & Gamble Company Intellectual Property Division

20070009460 - Method of forming an antiperspirant: Antiperspirant actives of aluminum and aluminum-zirconium of enhanced efficacy containing strontium and an amino acid that have a stable high HPLC Band III/II ratio are disclosed. The invention also discloses method for making the antiperspirant actives.... Agent: Arthur J. Plantamura General Chemical Performance Products LLC.

20070009459 - Stabilized antiperspirant compositions containing soy products: This invention relates to antiperspirant compositions comprising soy products, one ore more antiperspirant agents such as aluminium chlorohydrate and a stabilizing system, which additionally influence hair growth.... Agent: Philip S. Johnson Johnson & Johnson

20070009461 - Hair treatment compositions: The invention provides a rinse off hair treatment composition comprising a salt. The composition is for lengthening and straightening hair.... Agent: Unilever Intellectual Property Group

20070009465 - Cosmetic compositions comprising polyol/polyester block polymers: A cosmetic composition is described, said composition having a content of a block polymer having at least a first block, which block is a polyol selected from polyethers, dimerdiol, derivatives derived from dimerdiol and polyesters of dicarboxylic acids with diols and at least two additional blocks, which blocks are polyesters... Agent: Seed Intellectual Property Law Group PLLC

20070009464 - Process for the preparation of hydroxy polymer esters and their use: This invention covers a novel method for the preparation of hydroxy polymer esters of amino, alkylamino and quaternary ammonium acids and their use in several fields of industry, incuding the use as additives in the manufacture of paper or paperboard. The esterification of the hydroxy polymer, preferably starch, is performed... Agent: Ciba Specialty Chemicals Corporation Patent Department

20070009466 - Durable wrinkle hiding & moisturizing facial cosmetic: A facial cosmetic containing silica, boron nitride, and a water resistant resin... Agent: Theodore Jay

20070009467 - Spray-on makeup to simulate the appearance of wearing hosiery: A fast drying, spray-on cosmetic preparation containing pigments and texturants to simulate the appearance of wearing hosiery when applied to human skin. Specific tailoring of ranges of sizes for pigment and texturant particles simulates the color and texture appearance of hosiery in a durable, removable makeup that smoothes and moisturizes... Agent: Morrison & Foerster LLP

20070009468 - Photodynamic method of inducing the growth of hair: Disclosed herein is a method of inducing the growth of hair on the skin of a human, such as the scalp, the method comprising systemically or topically altering the hormonal status of the skin, such as with androgen blockers or estrogen-like hormones, and exposing the skin to at least one... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070009470 - Topical/on-the-skin estrogen cream, lotion, ointment, hair tonic, shampoo and wound healing powder: The Claimed Invention is the topical-to-skin use of generic estradiol, estriol, conjugated estrogens, or any other synthetic estrogen within a non-absorbable generic vehicle of cream, lotion, ointment, shampoo, hair tonic, and wound-healing powder, having no absorbents or deconstructors in their formulas. This invention causes skin basal cells to produce increased... Agent: Kin S. Jung, Md

20070009469 - Treatment of skin, and wound repair, with thymosin beta 4: Compositions and methods for treatment of skin utilizing thymosin β4.... Agent: Rothwell, Figg, Ernst & Manbeck, P.C.

20070009471 - Cosmetic composition with watertight fragrance: The present invention refers to a cosmetic composition which, in particular, enables the perfume component resist wash off by water and sweat and to remain fixed on the skin for a long time watertightly. The cosmetic composition comprises fragrance and a fragrance-fixing complex consisting of 0.01-10% by weight of a... Agent: Millen, White, Zelano & Branigan, P.C.

20070009462 - Composition to permanently reshape the hair containing at least one dicarboxydithiol: A either represents (CH2)n where n is an integer ranging from 1 to 4, or a —(CH2)m—X—(CH2)p— radical, where m is 1 or 2, p is 1 or 2 and X represents O, S, NHCO or NR6, where R6 represents H or CH3, and/or one or more organic and mineral... Agent: Thomas L. Irving Finnegan, Henderson, Farabow

20070009472 - Personal care compositions comprising a non-binding thickener with a metal ion: Personal care composition comprising an effective amount of a zinc containing material; a surfactant; a cationic, or a nonionic thickening polymer, or a mixture thereof. The present invention may be a multi-phase personal care composition comprising: at least two phases wherein at least one of the phases comprises an effective... Agent: The Procter & Gamble Company Intellectual Property Division

20070009463 - Rheology profile for a personal care composition: Personal care compositions comprising a desirable rheology profile. A method of delivering benefits to hair or skin is provided.... Agent: The Procter & Gamble Company Intellectual Property Division

20070009474 - Personal care compositions and methods for the beautification of mammalian skin and hair: Personal care composition comprising from about 0.05% to about 5% of at least one aquaporin-stimulating compound selected from the group consisting of xanthine, caffeine; 2-amino-6-methyl-mercaptopurine; 1-methyl xanthine; 2-aminopurine; theophylline; theobromine; adenine; adenosine; kinetin; p-chlorophenoxyacetic acid; 2,4-dichlorophenoxyacetic acid; indole-3-butyric acid; indole-3-acetic acid methyl ester; beta-naphthoxyacetic acid; 2,3,5-triiodobenzoic acid; adenine hemisulfate; n-benzyl-9-(2-tetrahydropyranyl)adenine;... Agent: The Procter & Gamble Company Intellectual Property Division

20070009473 - Vintage dated wine soap: This vintage dated wine soap is a hand made cleansing agent intended for use by humans and on certain animals. It combines vintage dated wine with various oils and fragrances in a cold blending process that preserves the characteristics of the wine, including the color, aromas and astringency. The glycerin... Agent: Robert Wilford Walker

20070009475 - Aminoalkyl substituted esters and amides of fumaric acid for neutralizing malodor: The present invention relates to aminoalkyl substituted fumarates and there use as malodor neutralisers.... Agent: Norris, Mclaughlin & Marcus

20070009476 - Multivalent aptamer therapeutics with improved pharmacodynamic properties and methods of making and using the same: Materials and methods are provided for producing aptamer therapeutics having improved pharmacokinetic and pharmacodymanic properties, as well as increased target valency. The aptamers produced by the methods of the invention are useful as therapeutics for treating disease.... Agent: Mintz, Levin, Cohn, Ferris, Glovsky And Popeo, P.C.

20070009477 - Methods for rational pegylation of proteins: The present invention relates to the use of simulation technology to rationally optimize the locations and sizes of attached polymeric moieties for modification of therapeutic proteins and the proteins generated from this method.... Agent: Robin M. Silva, Esq. Dorsey & Whitney LLP

20070009478 - Pegylated g-csf polypeptides and methods of producing same: A method for increasing the stability and uniformity of a PEGylated G-CSF polypeptide having at least one PEG moiety attached to the epsilon amino group of a lysine residue or the N-terminal amino group and at least one PEG moiety attached to a hydroxyl group, comprising subjecting the polypeptide to... Agent: Maxygen, Inc. Intellectual Property Department

20070009479 - Methods for treating dermatitis using mutant human il-4 compositions: Methods of administering a therapeutically effective amount of a mutant human IL-4 composition to a human subject for the amelioration and treatment of dermatitis, including contact and atopic dermatitis.... Agent: Dla Piper US LLP

20070009480 - Low-toxicity, long-circulating human interferon-alpha analogs: Interferon-alpha (IFNα) analog proteins modified by chemical attachment of at least one hydrophilic polymer moiety, such as polyethylene glycol chain, are described. In one embodiment, the IFNα analog protein has an amino acid sequence that differs from a native human IFNα interferon-alpha by one or more amino acid residues in... Agent: Perkins Coie LLP

20070009486 - Adenoviral vectors having a protein ix deletion: This invention provides a recombinant adenovirus expression vector characterized by the partial or total deletion of the adenoviral protein IX DNA and having a gene encoding a foreign protein or a functional fragment or mutant thereof. Transformed host cells and a method of producing recombinant proteins and gene therapy also... Agent: Townsend And Townsend And Crew, LLP

20070009483 - Compositions and methods for the therapeutic treatment of diabetes: The invention provides a vector having a nucleic acid operably linking a promoter, an intron, a secretory leader sequence encoding nucleic acid, a human betacellulin (BTC) encoding nucleic acid, or functional fragment thereof, and a polyadenylation signal sequence, wherein expression of BTC produces a secreted, mature BTC. Also provided is... Agent: Mcdermott Will & Emery LLP Attn: Intellectual Property Deptartment

20070009484 - Compositions and methods involving mda-7 for the treatment of cancer: The present invention concerns methods and compositions involving MDA-7 protein or an MDA-7-encoding nucleic acid in combination with either 1) a COX-2 selective inhibitor, such as celecoxib, 2) an Hsp90 inhibitor, such as geldanamycin, or a geldanamycin derivative or analog, 3) a vitamin E compound, for the treatment of cancer,... Agent: Fulbright & Jaworski L.L.P.

20070009488 - Feline granulocyte macrophage colony stimulating factor nucleic acid molecules: The present invention relates to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine interleukin-13, feline interferon alpha, and/or feline GM-CSF proteins; to canine interleukin-4, canine or feline Flt-3 ligand, canine or feline CD40, canine or feline CD154, canine interleukin-5, canine... Agent: Heska Corporation Intellectual Property Dept.

20070009482 - Immunomodulatory oligonucleotides: Oligonucleotides containing unthylated CpG dinucleotides and therapeutic utilities based on their ability to stimulate an immune response in a subject are disclosed. Also disclosed are therapies for treating diseases associated with immune system activation that are initiated by unthylated CpG dinucleotides in a subject comprising administering to the subject oligonucleotides... Agent: Wolf Greenfield & Sacks, PC

20070009487 - Minimal promoters and uses thereof: Minimal promoter sequences are described. Reagents including a nucleic acid molecule which contains these minimal promoter sequences are also described. Methods for constructing these reagents, and methods for using these reagents are also described.... Agent: Foley And Lardner LLP Suite 500

20070009485 - Nucleic acid delivery: The present invention provides formulations and methods to enhance the delivery of nucleic acids to cells. Formulations comprising dextrin polymers in combination with sugars provide enhanced delivery of nucleic acids, particularly eucaryotic expression vectors, demonstrate enhanced delivery of nucleic acids to cells in vivo. The present invention also provides methods... Agent: Townsend And Townsend And Crew, LLP

20070009481 - Use of fak-related non-kinase in the manufacture of a medicament for the inhibition of stenosis and restenosis: The present invention is related to the use of an adeno-associated virus, whereby the adeno-associated virus comprises a) FRNK or a derivative thereof, or b) a nucleic acid encoding FRNK or a derivative thereof, or of a nucleic acid coding for an adeno-associated virus, whereby the nucleic acid comprises a... Agent: Wood, Phillips, Katz, Clark & Mortimer

20070009500 - Compositions and methods for the treatment of lysosomal storage disorders: The present invention relates to methods for providing lysosomal enzymes to a subject by administering stem cells, preferably Multipotent Adult Progenitor Cells (MAPCs). The invention further relates to methods for treating lysosomal storage disorders by administering stem cells.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070009497 - Dendritic cell expanded t suppressor cells and methods of use thereof: This invention relates to culture-expanded T suppressor cells and their use in modulating immune responses. This invention provides methods of producing culture-expanded T suppressor cells, which are antigen specific, and their use in modulating complex autoimmune diseases.... Agent: Pearl Cohen Zedek, LLP Pearl Cohen Zedek Latzer, LLP

20070009496 - Method of growing myocardial cells: The proliferation of cardiomyocytes is induced by expressing cyclin and CDK in the cardiomyocytes, and by suppressing the function or action of a Cip/Kip family protein or inhibiting the production of a Cip/Kip family protein. Among the Cip/Kip family proteins, it is preferable to suppress the function of p27KiP1 or... Agent: Hunton & Williams LLP Intellectual Property Department

20070009499 - Myoblast treatment of diseased or weakened organs: Bioengineering the regenerative heart or other body organ in need of greater muscle mass or improved blood perfusion provides a novel treatment for organ weakness or failure. In the case of cardiac failure treatment, on May 14, 2002, a 55-year-old man suffering ischemic myocardial infarction received 25 injections carrying 465... Agent: Heller Ehrman White & Mcauliffe LLP

20070009498 - Nucleic acid constructs useful for glucose regulated production of human insulin in somatic cell lines: Unique multifunctional nucleotide expression cassettes comprising a nucleotide sequence encoding a human protease driven by a glucose-regulatable promoter, a nucleotide sequence encoding human proinsulin having sites at its B-C and C-A junctions altered to permit cleavage by the human protease, and a CMV promoter driving the transcription of the nucleotide... Agent: Michael P. Morris Boehringer Ingelheim Corporation

20070009501 - Squamous cell carcinoma antigens and use therefor: The present invention relates to tumor antigens of the squamous epithelial carcinoma, nucleic acids encoding the same as well as antibodies directed against the same. The invention furthermore relates to methods for the generation of antigen presenting cells and T cells specific for such antigens. Eventually, the invention comprises diagnostic... Agent: Jenkins, Wilson, Taylor & Hunt, P. A.

20070009490 - Dried biotherapeutic composition, uses, and device and methods for administration thereof: A biotherapeutic composition containing rapidly activatable bacteria in a dry form, a device for administering such a composition and methods of treatment thereof are disclosed. A method for preparing the biotherapeutic composition itself, as well as a method for preparing the bacteria for such a composition is also disclosed.... Agent: Martin D. Moynihan Prtsi, Inc.

20070009489 - Genetically modified tumor-targeted bacteria with reduced virulence: The present invention is directed to mutant Salmonella sp. having a genetically modified msbB gene in which the mutant Salmonella is capable of targeting solid tumors. The present invention further relates to the therapeutic use of the mutant Salmonella for growth inhibition and/or reduction in volume of solid tumors.... Agent: Law Offices Of Albert Wai-kit Chan, LLC

20070009503 - Antibiotic, compositions containing the antibiotic, and methods for administering the antibiotic and/or said compositions to livestock: An antibiotic comprising a protease-resistant bacteriocin derived from a lactic acid bacterium, and compositions thereof, are disclosed. A feed composition for livestock comprising the antibiotic comprising a protease-resistant bacteriocin derived from a lactic acid bacterium is also disclosed. A method for preventing the growth of human food poisoning-causing bacteria in... Agent: Cermak & Kenealy LLP Acs LLC

20070009502 - Nutritional conjunctive support therapy for recovery in animals following stress or illness: A composition of probiotics, vitamins and minerals, electrolytes with glutamine and glucose along with medium chain triglycerides are provided as a supplement to animals. This is administered to cattle, calves, sheep, pigs, horses, dogs, and cats that are experiencing stress and or are undergoing medical drug therapy to treat conditions... Agent: Intellectual Property Department Dewitt Ross & Stevens S.c.

20070009493 - Chondrogenic compositions and methods of use: The invention provides a method of treatment joint and disk disease comprising administering to the subject in need thereof a novel composition comprising a substantially purified plurality of cells enhanced with at least one bioactive factor capable of causing at least a portion of the plurality of cells to express... Agent: Fox Rothschild LLP Princeton Pike Corporate Center

20070009495 - Method for treating or preventing systemic inflammation in formula-fed infants: The present invention is directed to a novel method for treating or preventing systemic inflammation in a formula-fed infant. The method administering to the infant a therapeutically effective amount of LGG in combination with at least one LCPUFA.... Agent: Nichole Andrighetti Nelson Mullins Riley & Scarborough, LLP

20070009492 - Multipotent postnatal stem cells from human periodontal ligament and uses thereof: The invention generally relates to postnatal periodontal ligament stem cells and methods for their use. More specifically, the invention relates in one aspect to postnatal periodontal ligament multipotent stem cells, use of the cells to generate periodontium, differentiation of the cells and methods of tissue cryopreservation.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070009491 - Platelet-derived growth factor-responsive neural precursor cells and progeny thereof: This invention provides platelet-derived growth factor-responsive neural precursor (PRP) cells and methods of producing such cells in vivo or in vitro. These cells can further be used to generate neurons, oligodendrocytes and/or astrocytes.... Agent: Pillsbury Winthrop Shaw Pittman LLP

20070009494 - Postpartum cells derived from umbilical cord tissue, and methods of making and using the same: Cells derived from human umbilical cords are disclosed along with methods for their therapeutic use. Isolation techniques, culture methods and detailed characterization of the cells with respect to their cell surface markers, gene expression, and their secretion of trophic factors are described.... Agent: Woodcock Washburn LLP

20070009504 - Pro-apoptotic agents: A substantially pure excretory-secretory product is isolatable from Necator americanus and is capable of inducing apoptosis in reactive T cells.... Agent: Saliwanchik Lloyd & Saliwanchik A Professional Association

20070009505 - Composition and system for wound decontamination: The present disclosure is directed to a cleansing solution and system for administering the cleansing solution to decontaminate a wound surface. A method and kit for decontaminating a wound surface is also provided.... Agent: Barnes & Thornburg LLP

20070009506 - Methods for production of recombinant urokinase: Highly efficient methods of producing properly folded recombinant urokinase are provided. Denatured recombinant pro-urokinase is refolded by first solubilizing the protein with a chaotroph at high pH, followed by refolding in the presence of reduced concentrations of chaotroph while the pH is slowly reduced.... Agent: Morrison & Foerster LLP

20070009507 - Fibrin citrulline derivatives and their use for diagnosing or treating rheumatoid arthritis: The invention concerns citrulline polypeptide derived from fibrin useful for diagnosing or treating rheumatoid arthritis.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070009509 - Antibody against nox1 polypeptide, method of diagnosing cancer with the use of nox1 gene and method of screening cancer growth inhibitor: The present invention provides a diagnostic method for cancer, a screening method for a cancer growth inhibitor, and a pharmaceutical composition used in cancer therapy using a Nox1 gene associated with a mutant Ras oncogene. More specifically, the present invention relates to: a composition for producing an antibody, comprising a... Agent: Reed Smith LLP

20070009508 - Methods for obtaining antibodies: The invention is directed towards a method of enriching a population of cells in those cells that produce an antibody which recognises an antigen of interest. In particular, an untagged antigen is used in conjunction with a polyclonal antibody to isolate cells recognizing said antigen.... Agent: Klauber & Jackson

20070009511 - Methods for treating immune disorders associated with graft transplantation with soluble ctla4 mutant molecules: The present invention provides use of soluble CTLA4 mutant molecules which bind with greater avidity to the CD80 and/or CD86 antigen than wild type CTLA4 or non-mutated CTLA4Ig in the treatment of immune disorders associated with graft transplantation.... Agent: Louis J. Wille Bristol-myers Squibb Company

20070009510 - Monoclonal antibodies against ricin toxin and methods of making and using thereof: Disclosed herein are monoclonal antibodies (Mabs) against ricin toxin and its subunits. The Mabs were initially selected based upon their ability to bind to ricin and its individual subunits in a solid-phase enzyme-linked immunoassay (ELISA). Several candidates were selected for further evaluation, including their ability to inhibit ricin intoxication in... Agent: Office Of The Staff Judge Advocate (sks) U.s. Army Med. Research & Material Command

20070009512 - Recombinant bivalent monospecific immunoglobulin having at least two variable fragments of heavy chains of an immunoglobulin devoid of light chains: The present invention relates to fragments, especially variable fragments of immunoglobulins which are by nature devoid of light chains, these fragments being nevertheless capable of exhibiting a recognition and binding activity toward specific antigens. The present invention further relates to the use of such immunoglobulin fragments formed of at least... Agent: Wolf Greenfield & Sacks, PC

20070009513 - Novel method of screening: The use of a G-protein coupled receptor protein comprising the same or substantially the same amino acid sequence as the amino acid sequence represented by SEQ ID NO: 1, or a salt thereof and a ligand peptide comprising the amino acid sequence represented by any of SEQ ID NO: 3... Agent: Mark Chao Takeda Pharmaceuticals North America Inc

20070009514 - Prostaglandin receptor ep1: e

20070009522 - Anti-rhesus d monoclonal antibodies: The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease... Agent: Foley And Lardner LLP Suite 500

20070009520 - Antibodies to ocif-binding molecules: A novel protein which binds to Osteoclastogenesis Inhibitory Factor (OCIF-binding molecule; OBM), a process for preparing the same, DNA encoding said protein, a protein having an amino acid sequence encoded by this DNA, a method for producing said protein by genetic engineering technique, and a pharmaceutical composition containing said protein.... Agent: Arnold & Porter LLP Attn:IPDocketing Dept.

20070009521 - Human tumor necrosis factor tr21 and methods based thereon: The present invention relates to TR21 polypeptides. In particular, isolated nucleic acid molecules are provided encoding human TR21 protein. TR21 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of TR21... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070009516 - Immune response-associated proteins: Various embodiments of the invention provide human immune response associated proteins (IRAP) and polynucleotides which identify and encode IRAP. Embodiments of the invention also provide expression vectors, host cells, antibodies, agonists, and antagonists. Other embodiments provide methods for diagnosing, treating, or preventing disorders associated with aberrant expression of IRAP.... Agent: Foley And Lardner LLP Suite 500

20070009519 - Immunoregulatory antibodies and uses thereof: A combination antibody therapy for treating B cell malignancies using an immunoregulatory antibody, especially an anti-B7, anti-CD23, or anti-CD40L antibody and a B cell depleting antibody, especially anti-CD19, anti-CD20, anti-CD22 or anti-CD37 antibody is provided. Preferably, the combination therapy will comprise anti-B7 and anti-CD20 antibody administration.... Agent: Pillsbury Winthrop Shaw Pittman, LLP

20070009515 - Inflammatory skin disease-related slurp-2 gene and utilization thereof: The present inventors used microarrays to identify a novel gene from cDNA clones showing significantly different gene expression in normal tissues compared to psoriasis lesion tissues. This gene was named secretory Ly-6/uPAR-related protein-2 (SLURP-2). Quantitative real-time RT-PCR analysis using total RNA extract was used to compare SLURP-2 gene expression between... Agent: Seed Intellectual Property Law Group PLLC

20070009517 - Method of inducing immune tolerance: Methods for inducing tolerance to a transplant in a subject are disclosed. The methods comprise administering multiple doses of a therapeutically effective amount of a CD40 antagonist alone or in combination with a CD86 antagonist, wherein the first dose of the antagonist is given before or at the time of... Agent: Darby & Darby P.C.

20070009518 - Methods for treating fibrotic conditions: The present invention is directed to methods for treating fibrosis conditions, such as liver, kidney and lung fibrosis, as well as fibrosis conditions of other tissues of the body. The methods of the invention comprise administering to a patient in need of such treatment a therapeutically effective amount of a... Agent: Sterne, Kessler, Goldstein & Fox, P.l.l.c.

20070009523 - Polypeptide variants with altered effector function: The present invention concerns polypeptides comprising a variant Fc region. More particularly, the present invention concerns Fc region-containing polypeptides that have altered effector function as a consequence of one or more amino acid modifications in the Fc region thereof.... Agent: Genentech, Inc.

20070009526 - Anti-il-23 antibodies, compositions, methods and uses: An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.... Agent: Philip S. Johnson Johnson & Johnson

20070009525 - Human endokine alpha and methods of use: The present invention concerns a novel member of the tumor necrosis factor (TNF) family of cytokines. In particular, isolated nucleic acid molecules are provided encoding the endokine alpha protein. Endokine alpha polypeptides are also provided, as are vectors, host cells and recombinant methods for producing the same. Also provided are... Agent: Human Genome Sciences Inc. Intellectual Property Dept.

20070009527 - Method for cloning of variable domain sequences: The present invention relates to a method for cloning immunoglobulin variable domain sequences derived from immunoglobulins, and a repertory library of immunoglobulin variable domain sequences made according to the method.... Agent: Wolf Greenfield & Sacks, PC

20070009524 - Methods of treating inflammation associated with viral infection with anti-tnf antibodies: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of... Agent: Hamilton, Brook, Smith & Reynolds, P.C.

20070009529 - Agents that dissolve arterial thrombi: Agents that induce platelet fragmentation include an IgG antibody that reacts with platelet epitope GPIIIA49-66 on platelet membrane, recombinant AMANTS-18, phorbol 12-myristate 13-acetate (PMA) and A23817.... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070009528 - Antibodies to masp-2: The invention relates to antibodies to MASP-2 and functional equivalents thereof. In particular, the invention relates to MASP-2 antibodies capable of inhibiting the function of MASP-2. The invention furthermore discloses MASP-2 epitopes, wherein antibodies recognising said epitopes are in particularly useful for inhibiting MASP-2 activity. The invention also relates to... Agent: Browdy And Neimark, P.l.l.c. 624 Ninth Street, Nw

20070009530 - Methods and compositions for inhibiting tumorigenesis: The present invention relates to compounds, small interfering RNAs and compositions and methods of inhibiting tumorigenesis and methods of inhibiting tumor cell growth and proliferation using agents that inhibit the hedgehog and Gli signaling pathway, including agents that inhibit GLI synthesis and/or function. The present invention also relates to particular... Agent: Klauber & Jackson

20070009536 - Novel madcam antibodies: The invention provides new, improved anti-MAdCAM antibodies. Uses of these antibodies in medicine are also included, in particular for the treatment of inflammatory conditions such as inflammatory bowel disease.... Agent: Pfizer Inc.

20070009533 - Treatment of cancer patients exhibiting activation of the p-glycoprotein efflux pump mechanism: The present invention relates to a method of determining P-glycoprotein expression and/or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to using a P-glycoprotein expression and/or function diagnostic in conjunction with methods for treating solid tumors, leukemias, and other malignancies with a chemotherapeutic... Agent: Knobbe Martens Olson & Bear LLP

20070009534 - Treatment of cancer patients exhibiting activation of the p-glycoprotein efflux pump mechanism: The present invention relates to a method of determining P-glycoprotein expression and/or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to using a P-glycoprotein expression and/or function diagnostic in conjunction with methods for treating solid tumors, leukemias, and other malignancies with a chemotherapeutic... Agent: Knobbe Martens Olson & Bear LLP

20070009535 - Treatment of cancer patients exhibiting activation of the p-glycoprotein efflux pump mechanism: The present invention relates to a method of determining P-glycoprotein expression and/or function for a patient with solid tumors, leukemias, and other malignancies. The invention also relates to using a P-glycoprotein expression and/or function diagnostic in conjunction with methods for treating solid tumors, leukemias, and other malignancies with a chemotherapeutic... Agent: Knobbe Martens Olson & Bear LLP

20070009531 - Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar: The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar and a calicheamicin-antibody conjugate, such as Mylotarg. The invention is also directed to pharmaceutical formulations comprising zosuquidar and calicheamicin-antibody conjugates. The formulations are particularly effective in treating relapsed... Agent: Knobbe Martens Olson & Bear LLP

20070009532 - Treatment of patients with cancer using a calicheamicin-antibody conjugate in combination with zosuquidar: The present invention relates to a method of treating patients with solid tumors, leukemias, and other malignancies using a combination of zosuquidar and a calicheamicin-antibody conjugate, such as Mylotarg. The invention is also directed to pharmaceutical formulations comprising zosuquidar and calicheamicin-antibody conjugates. The formulations are particularly effective in treating relapsed... Agent: Knobbe Martens Olson & Bear LLP

20070009537 - Antimicrobial activity of antibodies producing reactive oxygen species: The invention provides compositions having antibodies that can generate reactive oxygen species when exposed to singlet oxygen, as well as methods of using the compositions, for example, to treat microbial infections.... Agent: Schwegman, Lundberg, Woessner & Kluth, P.A.

20070009539 - Drug conjugate composition: The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that... Agent: Leydig Voit & Mayer, Ltd

20070009540 - Drug conjugate composition: The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that... Agent: Leydig Voit & Mayer, Ltd

20070009541 - Drug conjugate composition: The invention provides a liquid composition and a lyophilized composition comprising a therapeutically effective amount of a conjugate comprising an antibody chemically coupled to a maytansinoid. The invention further provides a method for killing a cell in a human comprising administering to the human either of the compositions such that... Agent: Leydig Voit & Mayer, Ltd

20070009538 - Expression and export of angiogenesis inhibitors as immunofusins: A homodimeric protein of the invention has angiogenesis inhibiting activity. The homodimeric protein consists of two identical fusion proteins bound together as a homodimer. Each fusion protein comprises an immunoglobulin Fc region and a first target protein linked to the immunoglobulin Fc region. The first target protein has an angiogenesis... Agent: Olson & Hierl, Ltd.

20070009542 - Method and device for transdermal immunization: The present invention relates to methods and device for transdermal immunization. More particularly, the invention relates to a device for effective topical administration of antigens comprising an apparatus that generates micro-channels in the skin of a subject. The delivery system is useful for immunization against bacterial, viral, and fungal antigens... Agent: Pepper Hamilton LLP

20070009544 - Anti-allergic complex molecules: The present invention discloses novel therapeutic complex molecules, and in particular, peptidic or peptidomimetic molecules, comprising a first part which is competent for cell penetration and a second part which is able to reduce or abolish mast cell degranulation, in particular to reduce or abolish allergy mediators, including histamine secretion... Agent: Prtsi, Inc.

20070009543 - Protein involved in ovarian cancer: The present invention relates to new uses of CDCP1 in the diagnosis, screening, treatment and prophylaxis of ovarian cancer. The invention also provides compositions comprising CDCP1, including vaccines, antibodies that are immunospecific for CDCPI and agents which interact with or modulate the expression or activity of CDCP1 or which modulate... Agent: Klauber & Jackson

20070009545 - Mycoplasma subunit vaccine: The present invention relates i.a. to vaccines for combating Mycoplasma infection, to mycoplasmal L-α-glycerophosphate oxidase for use in such vaccines, to the use of mycoplasmal L-α-glycerophosphate oxidase for the manufacturing of such vaccines, to methods for the preparation of such vaccines and to diagnostic tests for the discrimination of animals... Agent: Intervet Inc. Patent Department

20070009546 - Purified polypeptides from streptococcus pneumoniae: The invention provides novel polypeptides and polynucleotides encoding such polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are methods for utilizing such polypeptides to screen for antibacterial compounds.... Agent: Goodwin Procter LLP Patent Administrator

20070009547 - Modified esat-6 molecules and improved vaccine strains of mycobacterium bovis bcg: A genetically modified strain of M. tuberculosis or Mycobacterium bovis BCG is provided, wherein the genetically modified strain comprises at least one modified sequence comprising SEQ ID NO: 1, SEQ ID NO: 2, or both, having at least one mutation at T2, Q4, F8, A14, L28, L29, W43, G45, Q55,... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070009548 - Inactivated chimeric and related methods of use: Embodiments of the present invention generally provide an inactivated chimeric virus vaccine and/or immunogenic composition for the treatment or prevention of viral infection. Further, various other embodiments of the present invention generally relate to methods of preventing and treating virus infection in such animals with the inactivated vaccine and/or immunogenic... Agent: Intervet Inc. Patent Department

20070009549 - Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response: The present invention relates to HIV-1 envelope proteins from a donor with non-progressive HIV-1 infection whose serum contains broadly cross-reactive, primary virus neutralizing antibody. The invention also relates to isolated or purified proteins and protein fragments that share certain amino acids at particular positions with the foregoing HIV-1 proteins.... Agent: Morgan Lewis & Bockius LLP

20070009550 - Postweaning multisystemic wasting syndrome and porcine circovirus from pigs: The cloning of a novel PCVII viral genome is described as is expression of proteins derived from the PCVII genome. These proteins can be used in vaccine compositions for the prevention and treatment of PCVII infections, as well as in diagnostic methods for determining the presence of PCVII infections in... Agent: Frommer Lawrence & Haug

20070009551 - Aids ancestral viruses and vaccines: The present invention is directed to ancestral HIV nucleic acid and amino acid sequences, methods for producing such sequences and uses thereof, including prophylactic and diagnostic uses.... Agent: Fish & Richardson PC

20070009552 - Dengue tetravalent vaccine containing a common 30 nucleotide deletion in the 3'-utr of dengue types 1,2,3, and 4, or antigenic chimeric dengue viruses 1,2,3, and 4: The invention relates to a dengue virus tetravalent vaccine containing a common 30 nucleotide deletion (Δ30) in the 3′-untranslated region of the genome of dengue virus serotypes 1, 2, 3, and 4, or antigenic chimeric dengue viruses of serotypes 1, 2, 3, and 4.... Agent: Knobbe Martens Olson & Bear LLP

20070009553 - Bacterial strains of genus exiguobacterium, culture method and uses: The invention concerns bacterial strains of genus Exiguobacterium. Said strains are thermoresistant, capable of growing on sugar and starch substrates and/or capable of producing metabolites such as L(+) lactate. The invention is useful for producing metabolites such as L(+) lactate.... Agent: Nixon & Vanderhye, PC

20070009554 - Biologically active hemagglutinin from type a clostridium botulinum and methods of use: An isolated, biologically active 33 kDa hemagglutinin purified from the type A Clostridium botulinum neurotoxin complex and its uses are described.... Agent: Fish & Richardson PC

20070009555 - Botulinum toxin and the treatment of primary disorders of mood and affect: The invention provides methods for treating primary disorders of mood and affect, including depressive disorders, anxiety and sleep disorders and CNS disorders comprising the administration of a neurotoxin.... Agent: Milbank, Tweed, Hadley & Mccloy LLP

20070009556 - Live genetically attenuated malaria vaccine: Method for inoculating a vertebrate host against malaria, by administering to the host a live Plasmodium organism that is genetically engineered to disrupt a liver-stage-specific gene function.... Agent: Christensen, O'connor, Johnson, Kindness, PLLC

20070009559 - Free-flowing solid formulations with improved bio-availability of poorly water soluble drugs and process for making the same: A free-flowing solid formulations of drugs or pharmaceutical agents which have poor aqueous solubility are obtained by admixing a liquid or gel composition that includes 1 to 30 percent by weight of the drug, 5 to 60 percent by weight of a surfactant, 10 to 40 percent by weight of... Agent: Gabor L. Szekeres

20070009557 - Moldable implant material: A moldable implant material is described which is characterized in that a biodegradable or biocompatible monofilament or polyfilament thread is formed e.g. of polyester, polyamide, a corrodible iron alloy, magnesium, magnesium alloys, polysaccharides, polysaccharide derivatives, proteins, and/or protein derivatives or of combinations of these materials in such a way that,... Agent: Kurt G. Briscoe Norris, Mclaughlin & Marcus P.A.

20070009558 - Sugar-free storage-stable antihistaminic syrups: New and improved antihistaminic syrups are disclosed.... Agent: Schering-plough Corporation Patent Department (k-6-1, 1990)

20070009560 - Cosmetic and dermatological agent containing magnetic particles production thereof and use of the same: The invention relates to a cosmetic and dermatological agent containing magnetically hard particles and other active ingredients. Said agent contains 0.0001 to 2 wt. % of magnetically hard particles, preferably barium hexaferrite single crystals of between 80 and 550 nm and with a coercive force ranging from 80,000 to 1,600,000... Agent: Akerman Senterfitt

20070009562 - Spherical optical structure: Disclosed herein is a spherical optical structure having a particle diameter less than or equal to 500 μm, comprising a core substance and a coating substance coating the core substance, wherein the particle diameter and/or the thickness of the coating substance of the spherical optical structure are controlled to be... Agent: Finnegan, Henderson, Farabow, Garrett & Dunner LLP

20070009561 - Tablets resistant to shock loads: The invention relates to tablets consisting of pressed particulate washing or cleaning agents and comprising at least two reinforcing grooves on the upper side thereof, the horizontal extension of said grooves on the plane of the tablet surface being longer than the depth thereof. The inventive tablets are characterized by... Agent: Paul & Paul

20070009563 - Process for coating fiber or fabric with insecticide using a temperature of 150°c-190°c for drying: Conventionally, fiber coated with insecticide is dried at a temperature not higher than 100° C., which prevents the insecticide from degrading. However, according to the present invention, polyester fabric, or other fabrics or fibers, is dipped in an insecticide mixture comprising a pyrethroid substance or other insecticide, a thickener, a... Agent: Brenc Law Andrew Brenc

20070009564 - Drug/polymer composite materials and methods of making the same: A method of forming a drug/polymer composite material is carried out by combining a drug material with a polymer material under pressure in the presence of a compressed gas solvent (e.g., carbon dioxide) to form the drug/polymer composite material. Drug/polymer composite materials and shaped articles (e.g., subcutaneous drug depots) which... Agent: Wilson Sonsini Goodrich & Rosati

20070009565 - Functionalized chemically inert polymers for coatings: Provided herein are methods for functionalizing an polymer for forming a coating and coatings and devices formed thereof or for functionalizing a coating or device surface including an polymer.... Agent: Squire, Sanders & Dempsey LLP

20070009566 - Method and apparatus for treating bacterial infections in devices: An apparatus and method for treating or preventing bacterial colonization of medical devices, or the host itself, comprise combining an RNAIII inhibiting peptide (RIP) with the medical device, optionally with an antibiotic. Further, RIP may be used in a lock technique, comprising adding sufficient solution comprising RIP to occupy a... Agent: Merchant & Gould PC

20070009570 - Method for preparing porous polymer scaffold for tissue engineering using gel spinning molding technique: The present invention relates to a method of preparing a porous polymer scaffold for tissue engineering using a gel spinning molding technique. The method of the present invention can prepare a porous polymer scaffold having a uniform pore size, high interconnectivity between pores and mechanical strength, as well as high... Agent: Jones Day

20070009567 - Methods and compositions for the treatment and prevention of staphylococcal infections: Methods and compositions are provided for the treatment of staphylococcal infections.... Agent: Merchant & Gould PC

20070009569 - Methods and compositions for the treatment and prevention of staphylococcus and other bacterial infections: The invention features methods and compositions for treatment or prevention of infection by, or disease caused by infection with, certain species of bacteria, including in particular bacteria in which a RAP-type and/or TRAP-type molecule plays a role in pathogenesis. This includes Staphylococcus species.... Agent: Merchant & Gould PC

20070009568 - Methods for immobilizing molecules on surfaces: The invention provides methods for immobilizing molecules on metallic surfaces, and compositions containing one or more surfaces that have been treated by these methods. The compositions may be used, e.g., to improve or repair cell, tissue, organ, or whole-body function.... Agent: Wilson Sonsini Goodrich & Rosati

20070009571 - Novel haptotactic peptides: A group of novel peptides having a sequence selected from the group consisting of KGSWYSMRKMSMKIRPFFPQQ (SEQ ID NO:1), KTRWYSMKKTTMKIIPFNRL (SEQ ID NO:2) and RGADYSLRAVRMKIRPLVTQ (SEQ ID NO:3) are provided. Compositions and methods of use of these peptides are also provided.... Agent: Winston & Strawn LLP Patent Department

20070009573 - Method of forming immediate release dosage form: Provided among other things is a method of making an elongate dosage form comprising: providing an elongate core with two ends and a waist, the core comprising a bioactive agent and a release agent that swells on contact with water; coating the core with a polymer coating; enrobing the ends... Agent: Law Offices Of Arthur E. Jackson

20070009572 - Micro-structured and nano-structured surfaces on biodegradable polymers: In embodiments of the present invention, a biodegradable/biodegradable polymer film may be used as a scaffold for tissue engineering scaffolds for engineering organized organs, such as vascular grafts, for example. In one embodiment, an ultraviolet (UV) resin made from a diacrylated biodegradable oligomer is molded into a flexible scaffold having... Agent: Blakely Sokoloff Taylor & Zafman

20070009574 - Food product providing sustained blood levels of exogenous substances: The present invention relates to a food product comprising soluble fibre and at least one exogenous biologically active substance. It further relates to the uses of a mixture comprising at least soluble fibre and at least one exogenous substance in the preparation of a food product to avoid short-term peaks... Agent: Bell, Boyd & Lloyd LLC

20070009575 - Novel use of antisecretory factor: The present invention relates to the use of an antisecretory protein or homologues thereof having the same properties, or certain fragments thereof in the manufacture of a medicament or a medical food for inducing improved rescue of injured or diseased nervous tissue, proliferation, apoptosis, differentiation and/or migration of an embryonic... Agent: Buchanan, Ingersoll & Rooney PC

20070009576 - Nutritionally fortified liquid composition with added value delivery systems/elements/additives: A shelf-stable, ready to use, water-like composition for humans/animals; as an adjunct to fiber-water, and/or safe drinking water, consumed directly, tube feedings, or in the preparation/reconstitution of food(s)/beverage(s). Fortified Fiber-Water is fiber-water, with added delivery systems: Encapsulations/particles, of different size(s), shape(s), material(s), colors, non-visible, serving one or more functions: improved... Agent: Patton Boggs LLP Attorneys At Law

20070009577 - Probiotic compositions and methods: A variety of human and animal diseases are associated with distortion of diversity of intestinal flora caused by such factors as unnatural diet and exposure to antibiotics. Probiotic compositions according to the present invention and methods for their generation are described which are designed to provide exposure to microorganisms in... Agent: Julie K. Staple Gifford, Krass, Groh, Sprinkle

20070009578 - Haemostatic composition comprising hyaluronic acid: The present invention relates to a haemostatic composition comprising a biologically absorbable material and hyaluronic acid or a derivative thereof, methods of producing such compositions and the use of these compositions. In particular the method of producing said haemostatic composition comprises treating it with dry heat at a temperature between... Agent: Hunton & Williams LLP Intellectual Property Department

20070009581 - Multicomponent material comprising chitosan: A multicomponent material, which is comprised of chitosan material being coated onto an inert carrier material. The multicomponent material can be incorporated into an absorbent structure. In one aspect of the invention, the multicomponent material can be incorporated throughout the thickness of an absorbent structure. Absorbent articles comprising the multicomponent... Agent: The Procter & Gamble Company Intellectual Property Division

20070009580 - Non-adhesive hydrogels: Substantially non-adhesive hydrogels are useful as wound dressings, wound barriers, therapeutic drug delivery devices and the like. The substantially non-adhesive hydrogels are synthesized by a method that comprises irradiating a solution comprising a biological polymer that is biodegradable and biocompatible, using ionizing radiation, whereby free radicals of the biological polymer... Agent: Boyle Fredrickson Newholm Stein & Gratz, S.c.

20070009579 - Polysaccharide pseudo-sponge: wherein Si represents an area of the test specimen before the immersion, and S2 is an area of the test specimen after the immersion, in which the area is calculated from the length and width of the test specimen; and (II) an absorbance of not more than 0.15 at a... Agent: Nixon & Vanderhye, PC

20070009585 - Collagen substrate, method of manufacturing the same, and method of using the same: In order to provide a substrate for medical applications, which may be freely elastically deformed depending on a shape of a defective portion or hemostasis portion in a living body, is biocompatible and suitable for tissue regeneration or cell proliferation, or hemostasis, and can be easily manufactured. A collagen substrate... Agent: Kubovcik & Kubovcik

20070009582 - Composition useful as an adhesive and use of such a composition: A pressure sensitive adhesive composition comprising one or more hydrogel-forming hydrophilic homopolymers or heteropolymers and one or more amphiphilic block-copolymers comprising hydrophobic polymer blocks being incompatible and hydrophilic polymer blocks is useful, for example, in transdermal drug delivery systems and other medical, pharmaceutical and cosmetic products that adhere to the... Agent: Jacobson Holman PLLC

20070009583 - Dressing: A wound dressing for release of one or more therapeutic ingredients wherein the therapeutic ingredients are contained in liposomes, said liposomes may comprising releasing means being triggered by a wound constituent and thereby releasing the therapeutic ingredients of the liposomes. The dressing further comprises wound exudates handling means and is... Agent: Jacobson Holman PLLC

20070009584 - Manually-operable wound pressurization/depressurization system and method: A wound treatment apparatus may include an impermeable or semi-permeable dressing, a securement strap on the dressing for securing the dressing over a wound on a patient, and a pressure/vacuum generator in fluid communication with the dressing. A wound treatment method utilizing the wound treatment apparatus may include placing the... Agent: Walter W. Duft Law Offices Of Walter W. Duft

20070009586 - Wound dressings containing complexes of transition metals and alginate for elastase sequestering: Transition metal (e.g., silver and copper) derivatized phosphorylated polysaccharides (cellulose, starch, gauze) provide antimicrobial and elastase sequestration properties to wound dressings, and the wound dressing have enhanced water sorption and elastase sequestration when used with alginates. Wound dressings with alginates (e.g., silver alginate, crosslinked alginates, etc.) provide enhanced wound fluid... Agent: Whitham, Curtis & Christofferson & Cook, P.C.

20070009587 - Method and device for coating a continuous strip of microprojection members: The present invention provides a device and method for selectively providing multiple applications of an agent formulation on the skin piercing portions of a microprojection member to form an agent-containing coating on the microprojections. The formulation is dried to form a solid coating which contains the agent. A continuous conveyor... Agent: Philip S. Johnson Johnson & Johnson

20070009588 - Adhesive patch: An adhesive patch for percutaneous fentanyl administration which is easily produced, has long-term continuity, and is excellent in adhesion and conformability to the skin. The adhesive patch comprises a backing layer and a pressure-sensitive adhesive layer formed on one side thereof, wherein the pressure-sensitive adhesive layer comprises fentanyl as an... Agent: Kathleen Tyrrell Licata & Tyrrell

20070009589 - Extended release compositions: Pharmaceutical compositions of metoprolol or a salt have water-insoluble inorganic cores such as dibasic calcium phosphate having the drug deposited thereon, optionally with one or more hydrophilic or hydrophobic polymers or mixtures thereof, and an outer coating of a polymer blend utilizing groups of polymers having opposing wettability characteristics.... Agent: Dr. Reddy's Laboratories, Inc.

20070009591 - Ace inhibitor formulation: A process for preparing pharmaceutical micro-tablets comprises (a) preparing a tableting mix that comprises an ACE inhibitor, for example moexipril hydrochloride, and excipient ingredients that comprise one or more lubricants; and (b) compressing the tableting mix in a tablet press, to form micro-tablets having an average uncoated weight of about... Agent: Harness, Dickey, & Pierce, P.l.c

20070009594 - Compositions and methods for treatment of cycle-related symptoms: Methods are provided for treating cycle-related symptoms through administration of at least one progestin and at least one estrogen to a female subject.... Agent: Woodcock Washburn LLP

20070009592 - Immediate release pharmaceutical granule compositions and a continuous process for making them: An immediate or fast release pharmaceutical granule composition comprising at least one drug (i) classifiable as Class II or Class IV of the Biopharmaceutical Classification System, wherein the said drug constitutes at least about 0.5% by weight and no more than 50% by weight of the composition, and further comprising... Agent: Clark & Elbing LLP

20070009593 - Methods of treating cancer: Methods for treating cancer are described herein. The methods include administering to an HIV-negative patient an m-calpain inhibitor such as ritonavir. Ritonavir or other m-calpain inhibitors can also be co-administered with other therapeutic agents such as a Cox-2 inhibitor, a taxane, or a proteasome inhibitor. Methods for determining whether a... Agent: Fish & Richardson PC

20070009590 - Physiologically active composition based on phosphatidylserine: This physiologically active composition contains, as physiologically active constituents, the components a) phosphatidylserine and/or lysophosphatidylserine (in each case “PS”) and b) at least one (lyso)phospholipid different from component a) and c) a serine source different from component a), for example L-serine and/or O-phospho-L-serine. In this composition, the components a) and... Agent: Fulbright & Jaworski, LLP

20070009595 - Sugar alcohol composition for tableting: A powdery sugar alcohol composition which is useful as a tableting excipient is provided. The composition of the invention consists essentially of a crystalline sugar alcohol and an amorphous sugar alcohol, provided that the composition comprises 2-12 wt % of amorphous sorbitol. By employing the sugar alcohol composition as tableting... Agent: Sughrue Mion, PLLC

20070009597 - Active substance combination comprising a compound with npy receptor affinity and a compound with 5-ht6 receptor affinity: The present invention relates to an active substance combination comprising at least one compound with neuropeptide Y-receptor affinity, preferably neuropeptide Y5-receptor affinity, and at least one compound with 5-HT6 receptor affinity, a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070009596 - Controlled drug release composition resistant to in vivo mechanic stress: The controlled release units of the present invention are capable of maintaining the drug/s sustained release properties along the gastro-intestinal tract without losing their mechanical resistance induced by the in vivo peristalsis. The formulations object of the present invention are based on a matrix consisting in a glyceryl ester in... Agent: Mark P Levy Thompson Hine

20070009598 - Sustained-release microgranules containging gingko biloba extract and the process for manufacturing these: The subject of the present invention is a new stable herbal drug formulation in the form of sustained-release microgranules containing Gingko Biloba extract as well as the process for preparing it.... Agent: Foley And Lardner LLP Suite 500

20070009599 - Asymmetrically coated table: A tablet for the controlled release of a drug. The tablet is in the form of an asymmetrically coated tablet so that immediate release or time-delayed release times can be precisely controlled and the extended release slab may provide zero-order or first-order extended release and pulsatile release depending on the... Agent: Wright, Lindsey & Jennings LLP

20070009600 - Antidepressant dosage form: The invention pertains to a dosage form 10 and to administering an antidepressant medicament 16 for an extended period of time in a rate-known dose.... Agent: Philip S. Johnson Johnson & Johnson

20070009601 - Composition and method for the treatment of water related ear disorders: This invention provides a method for the treatment of water related outer ear canal disorders comprising the steps of applying a water resistant and antimicrobial film topically to the external ear canal. The invention includes a composition for the treatment of water related outer ear canal disorders comprising a water... Agent: Birch Stewart Kolasch & Birch

20070009602 - Direct drug delivery system based on thermally responsive biopolymers: A method for delivering a drug depot of a compound of interest to a selected region in a subject. The method comprises administering a composition directly to said region of interest, the composition comprising the compound of interest to be delivered (such as an antiinflammatory agent or a chemotherapeutic agent)... Agent: Myers Bigel Sibley & Sajovec

20070009603 - Compositions comprising fenofibrate and atorvastatin: The present invention relates to pharmaceutical compositions in particulate form or in solid dosage forms comprising a combination of fenofibrate and the HMG CoA reductase inhibitor atorvastatin or a pharmaceutically active salt thereof, which upon oral administration provides a relative AUC0-24 value (AUCfibric acid/AUCatorvastatin) of between about 250 and about... Agent: Cheryl H Agris Phd

20070009604 - Process: A process for preparing particles of a substance, such as a protein or polypeptide, comprising: (a) preparing a first liquid comprising water, the substance and a modulator, wherein the modulator has a solubility in water which decreases with increasing temperature; and (b) contacting the first liquid with a second liquid... Agent: White & Case LLP Patent Department

20070009605 - Encapsulation of water soluble peptides: This invention relates to a process for preparing biodegradable microspheres and or nanospheres using an oil-in-water process for the controlled release of bioactive peptides.... Agent: Biomeasure, Incorporated

20070009606 - Manufacturing process, such as three dimensional printing, including binding of water-soluble material followed by softening and flowing and forming films of organic-solvent-soluble material: The invention includes biostructures which may be characterized as having substantially all of the organic-solvent-soluble material in the form of a network of irregularly shaped perforated films. The biostructure may further include particles of a substantially-insoluble material, which may be a member of the calcium phosphate family. The biostructure may... Agent: Hunton & Williams LLP Intellectual Property Department

20070009607 - Antibacterial/anti-infalmmatory composition and method: An antibacterial/anti-inflammatory composition and method wherein the pairing of synergistic active ingredients with a natural enhancer for a more efficacious formulation for topical application treatments is used. Active ingredients hydrocortisone 1% and benzoyl peroxide 10% are paired with Emu Oil to increase the percentage of absorption of the ingredients through... Agent: Edward M. Livingston, Pa

20070009608 - Composition comprising plant and/or fish oils and compounds comprising non-oxidizable fatty acid entities: The present invention concerns a composition prepared from a combination of plant oil and/or fish oil and a compound comprising non β-oxidizable fatty acid analogues, and the use of said composition for the preparation of a pharmaceutical or nutritional composition for the prevention and/or treatment of insulin resistance, obesity, diabetes,... Agent: Ladas & Parry LLP

20070009609 - Solid compositions containing combinations of lactoferrin, colostrum, and citrus pectin: A dietary supplement for mammalian consumption, and particularly human consumption, for the purpose of stimulating the immune system, inhibiting infection and increasing tissue repair and healing. Comprising colostrum, lactoferrin, and with modified citrus pectin as an optional component, the dietary supplement is administered in ‘mucosal delivery format’: a dosage form... Agent: Howrey LLP

20070009610 - Engineered osteochondral construct for treatment of articular cartilage defects: A method of growing chondrocytes on an allograft cancellous bone structure which had been previously treated by demineralization to form a cartilage repair implant comprises isolating allograft chondrocytes from articular cartilage of a donor other than the patient on which the implant is to be used, cultivating the isolated chondrocytes... Agent: John S. Hale Gipple & Hale

20070009611 - Treatment of wounds and compositions employed: A synthesized composition containing zinc ions, calcium ions, rubidium ions and/or potassium ions in a pharmaceutically acceptable carrier, which, when applied to an open wound, effectively modulates-the activity of at least MMP-2 and/or MMP-9 in the wound. A method for treatment of wounds is disclosed.... Agent: O'melveny & Myers LLP

20070009612 - Method for administering a composition to an animal: Methods are provided for administering a composition to an animal. The compositions include coral calcium, and also may include magnesium, calcified seaweed, Aquamin®, and at least one vitamin selected from a group consisting of vitamin A, B series vitamins such as B3, B5, vitamin C, D, and E.... Agent: Stephen T. Sullivan Suite 1140

20070009613 - Poisonless sulfur free of noxious ingredients and method for manufacturing the same: The present invention relates to a poisonless sulfur product free of noxious ingredients and a method for manufacturing the poisonless sulfur product free of noxious ingredients, which comprises the steps of: forming a sulfur composition by combining and mixing a 80˜90 wt. % of sulfur, 5˜10 wt. % of barley... Agent: Lee, Hong, Degerman, Kang & Schmadeka

20070009614 - Composition and method for treating hypertension: The present invention relates to a composition for the treatment and/or prevention of hypertension, said composition comprising an synergistic anti-hypertensive combination of a therapeutically effective amount of at least one angiotensin II inhibitor, and a therapeutically effective amount of at least one nitric oxide donor; said composition optionally further comprising... Agent: Foley & Lardner LLP

20070009615 - Compositions and methods for controlling glucose uptake: The invention relates to compositions comprising at least two inhibitors selected from the group consisting of an alpha amylase inhibitor, an alpha glucosidase inhibitor, and a sodium dependent glucose transporter inhibitor. The invention also provides methods of using the compositions for controlling glucose uptake.... Agent: Morrison & Foerster LLP

20070009616 - Pesticidal compositions: A pesticidal composition comprising (i) one or more essential oils selected from tagetes oil or a thymol containining oil such as thyme oil, or a mixture thereof, or components thereof which have insect repellent or deterrent properties, which have insect repellent or deterrent properties, wherein the total amount of such... Agent: Townsend And Townsend And Crew, LLP

20070009617 - Method for preventing fungal growth in plants: A natural, garlic extract-based fungicide and associated method of use which, as an alternative to conventional use of synthetic chemical fungicides, provides effective prevention and eradication of fungal infestation by a wide spectrum of fungal species.... Agent: David G. Henry

20070009618 - Composition for preventing atherosclerosis: The present invention provides a composition obtained by organic solvent extraction of defatted plant seed which is an atherosclerosis preventative agent. The present invention further provides a food and a pharmaceutical composition containing the composition, as well as a method of preventing an atherosclerotic disease.... Agent: C. Irvin Mcclelland Oblon, Spivak, Mcclelland, Maier & Neustadt, P.C.

20070009619 - Neutralizing agent for cavitating toxin: e

20070009620 - Cholesterol regulating agent: It is an object of the present invention to provide a HDL cholesterol-raising agent which can selectively raise or maintain HDL cholesterol level, an LDL cholesterol-lowering agent which can selectively lower LDL cholesterol level, a composition which can selectively raise of maintain HDL cholesterol level, a method for raising or... Agent: John L. Cordani Carmody & Torrance LLP

20070009621 - Correcting systemic androgen levels using eurycoma longifolia: A method for treating Systemic Androgen Deficiency, by administering Eurycoma longifolia, a plant native to South East Asia which regulates testosterone biosynthesis in vivo by, inter alia, impacting the activity of CYP17 (17-hydroxylase/17,20 lysase) and leutenizing hormone.... Agent: Pharmaceutical Patent Attorneys, LLC

20070009622 - Herbal extract having anti-virus activity and preparation of same: The invention relates to the herbal extract having anti-viral activity. More specifically, it relates to the herbal extract produced bv extracting the comminuted fruit of Fructus Ligustri Lucidi (privet fruit), Rhizoma Polygonati (sealwort) Herba Agrimoniae (agrimonia) Radix Rehmanniae Glutinosae Conquitae (steamed glutinous rehmannia) or the mixture thereof, with a low... Agent: Bacon & Thomas, PLLC